<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="069ca9bd-7d7e-4358-b1f2-ce3ab7bca189"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use INGREZZA </content>
      <content styleCode="bold">or INGREZZA SPRINKLE </content>
      <content styleCode="bold">safely and effectively.  See full prescribing information for INGREZZA.</content>
      <br/>
      <content styleCode="bold">     </content>
      <br/>
      <content styleCode="bold">INGREZZA</content>
      <content styleCode="bold">
         <sup>®</sup>
      </content>
      <content styleCode="bold"> (valbenazine) capsules, for oral use</content>
      <br/>
      <content styleCode="bold">INGREZZA</content>
      <content styleCode="bold">
         <sup>®</sup>
      </content>
      <content styleCode="bold"> SPRINKLE (valbenazine) capsules, for oral use</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval:  2017</content>
      <br/>
   </title>
   <effectiveTime value="20240430"/>
   <setId root="4c970164-cafb-421f-9eb5-c226ef0a3417"/>
   <versionNumber value="28"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="800981276" root="1.3.6.1.4.1.519.1"/>
            <name>Neurocrine Biosciences, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="55f449a1-4342-461a-8323-f5035fc97200"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20240502"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70370-2040" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>INGREZZA</name>
                        <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Valbenazine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="40"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5SML1T733B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VALBENAZINE TOSYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="54K37P50KH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VALBENAZINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="S870P55O2W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOMALT</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70370-2040-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20181214"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA209241" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20181214"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48327" displayName="purple" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">VBZ;40</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70370-1060" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>INGREZZA</name>
                        <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Valbenazine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="60"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5SML1T733B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VALBENAZINE TOSYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="54K37P50KH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VALBENAZINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="S870P55O2W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOMALT</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70370-1060-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20210423"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA209241" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210423"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48326" displayName="red" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Dark Red Body</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48327" displayName="purple" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Cap</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">VBZ;60</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70370-1080" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>INGREZZA</name>
                        <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Valbenazine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="80"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5SML1T733B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VALBENAZINE TOSYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="54K37P50KH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VALBENAZINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="S870P55O2W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOMALT</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70370-1080-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20171004"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA209241" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20171004"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48327" displayName="purple" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Purple opaque body and cap</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">VBZ;80</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70370-2048" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>INGREZZA</name>
                        <formCode code="C47916" displayName="KIT" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Valbenazine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" displayName="BLISTER PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70370-2048-6" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20181214"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="1" value="7"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>INGREZZA</name>
                              <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>valbenazine</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIM">
                                 <quantity>
                                    <numerator unit="mg" value="40"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="5SML1T733B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VALBENAZINE TOSYLATE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="54K37P50KH" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>VALBENAZINE</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GELATIN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C RED NO. 40</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C BLUE NO. 1</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="S870P55O2W" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ISOMALT</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM STEARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>STARCH, CORN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA209241" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20181214"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48327" displayName="purple" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">VBZ;40</value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="18" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="1" value="21"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>INGREZZA</name>
                              <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>valbenazine</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIM">
                                 <quantity>
                                    <numerator unit="mg" value="80"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="5SML1T733B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VALBENAZINE TOSYLATE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="54K37P50KH" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>VALBENAZINE</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GELATIN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C RED NO. 40</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C BLUE NO. 1</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="S870P55O2W" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ISOMALT</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM STEARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>STARCH, CORN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA209241" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20181214"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48327" displayName="purple" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">VBZ;80</value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="19" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA209241" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20181214"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70370-2046" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>INGREZZA</name>
                        <formCode code="C47916" displayName="KIT" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Valbenazine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" displayName="BLISTER PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70370-2046-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230818"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="1" value="14"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="70370-2040" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>INGREZZA</name>
                              <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>valbenazine</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIM">
                                 <quantity>
                                    <numerator unit="mg" value="40"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="5SML1T733B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VALBENAZINE TOSYLATE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="54K37P50KH" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>VALBENAZINE</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GELATIN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C RED NO. 40</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C BLUE NO. 1</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="S870P55O2W" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ISOMALT</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM STEARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>STARCH, CORN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA209241" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230818"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48327" displayName="purple" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">VBZ;40</value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="18" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="1" value="14"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="70370-1060" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>INGREZZA</name>
                              <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>valbenazine</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIM">
                                 <quantity>
                                    <numerator unit="mg" value="60"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="5SML1T733B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VALBENAZINE TOSYLATE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="54K37P50KH" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>VALBENAZINE</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GELATIN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C RED NO. 40</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C BLUE NO. 1</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="S870P55O2W" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ISOMALT</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM STEARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>STARCH, CORN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA209241" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230818"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48327" displayName="purple" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48326" displayName="red" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">VBZ;60</value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="18" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA209241" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230818"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70370-4040" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>INGREZZA Sprinkle</name>
                        <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Valbenazine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="40"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5SML1T733B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VALBENAZINE TOSYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="54K37P50KH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VALBENAZINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="S870P55O2W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOMALT</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70370-4040-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20240430"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA218390" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240430"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Pearl white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">VBZ;40</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70370-4060" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>INGREZZA Sprinkle</name>
                        <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Valbenazine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="60"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5SML1T733B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VALBENAZINE TOSYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="54K37P50KH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VALBENAZINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="S870P55O2W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOMALT</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70370-4060-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20240430"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA218390" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240430"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Pearl white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">VBZ;60</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70370-4080" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>INGREZZA Sprinkle</name>
                        <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Valbenazine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="80"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5SML1T733B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VALBENAZINE TOSYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="54K37P50KH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VALBENAZINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="S870P55O2W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOMALT</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70370-4080-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20240430"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA218390" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240430"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Pearl white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">VBZ;80</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="47805267-e9b1-424b-ad83-936b9bcedc68"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43683-2" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table>
                           <col width="607"/>
                           <col width="127"/>
                           <tbody>
                              <tr>
                                 <td>Boxed Warning</td>
                                 <td>8/2023</td>
                              </tr>
                              <tr>
                                 <td>Indications and Usage (<linkHtml href="#_1_INDICATIONS_AND">1</linkHtml>)  </td>
                                 <td>8/2023</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#_2_1_Dosing_and">2.1</linkHtml>)</td>
                                 <td>8/2023</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#_2_2_Administrative_Information">2.2</linkHtml>)</td>
                                 <td>4/2024</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (<linkHtml href="#_5_1_Depression_and">5.1</linkHtml>, <linkHtml href="#_5_2_Hypersensitivity_Reactions">5.2</linkHtml>, <linkHtml href="#_5_5_Neuroleptic_Malignant">5.5</linkHtml>, <linkHtml href="#_5_6_Parkinsonism">5.6</linkHtml>)     </td>
                                 <td>8/2023</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="BoxedWarning">
               <id root="57f5df30-d867-45c1-b6b2-985cd4858f63"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34066-1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="bold">WARNING: DEPRESSION AND SUICIDAL IDEATION AND BEHAVIOR IN PATIENTS WITH HUNTINGTON’S DISEASE</content>
               </title>
               <text>
                  <paragraph>VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington’s disease. Anyone considering the use of INGREZZA or INGREZZA SPRINKLE must balance the risks of depression and suicidal ideation and behavior with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician.</paragraph>
                  <paragraph>Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington’s disease <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_1_Depression_and">5.1</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: DEPRESSION AND SUICIDAL IDEATION AND BEHAVIOR IN PATIENTS WITH HUNTINGTON’S DISEASE </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">• Increases the risk of depression and suicidal thoughts and behavior in patients with Huntington’s disease (</content>
                           <content styleCode="bold">
                              <linkHtml href="#_5_1_Depression_and">5.1</linkHtml>
                           </content>
                           <content styleCode="bold">) </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">• Balance risks of depression, and suicidal ideation and behavior with the clinical need for treatment of chorea when considering the use of INGREZZA </content>
                           <content styleCode="bold">or INGREZZA SPRINKLE </content>
                           <content styleCode="bold">(</content>
                           <content styleCode="bold">
                              <linkHtml href="#_5_1_Depression_and">5.1</linkHtml>
                           </content>
                           <content styleCode="bold">)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">• Monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior (</content>
                           <content styleCode="bold">
                              <linkHtml href="#_5_1_Depression_and">5.1</linkHtml>
                           </content>
                           <content styleCode="bold">)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">• Inform patients, caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician (</content>
                           <content styleCode="bold">
                              <linkHtml href="#_5_1_Depression_and">5.1</linkHtml>
                           </content>
                           <content styleCode="bold">) </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">• Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation (</content>
                           <content styleCode="bold">
                              <linkHtml href="#_5_1_Depression_and">5.1</linkHtml>
                           </content>
                           <content styleCode="bold">)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_1_INDICATIONS_AND">
               <id root="218d6f6c-42b2-4e55-8f89-b2a1c1bd64fc"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1 </content>
                  <content styleCode="bold">INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with:</paragraph>
                  <paragraph>- tardive dyskinesia <content styleCode="italics">[see Clinical Studies (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_14_1_Tardive_Dyskinesia">14.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="xmChange">- chorea associated with Huntington’s disease <content styleCode="italics">[see Clinical Studies (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_14_2_Chorea_Associated">14.2</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>. </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>INGREZZA and INGREZZA SPRINKLE are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated for the treatment of adults with:<br/>     - tardive dyskinesia. (<linkHtml href="#_1_INDICATIONS_AND">1</linkHtml>)<br/>     - chorea associated with Huntington’s disease. (<linkHtml href="#_1_INDICATIONS_AND">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="5f94b121-6f66-40fe-a399-0fb4bed3cc4e"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2 </content>
                  <content styleCode="bold">DOSAGE AND ADMINISTRATION</content>
               </title>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Tardive dyskinesia: The initial dosage is 40 mg once daily. After one week, increase the dose to the recommended dosage of 80 mg once daily. (<linkHtml href="#_2_1_Dosing_and">2.1</linkHtml>)<br/>
                           </item>
                           <item>Chorea associated with Huntington’s disease: The initial dosage is 40 mg once daily. Increase the dose in 20 mg increments every two weeks to the recommended dosage of 80 mg once daily. (<linkHtml href="#_2_1_Dosing_and">2.1</linkHtml>)<br/>
                           </item>
                           <item>40 mg or 60 mg once daily may be considered depending on response and tolerability. (<linkHtml href="#_2_1_Dosing_and">2.1</linkHtml>)<br/>
                           </item>
                           <item>Can be taken with or without food. (<linkHtml href="#_2_2_Administrative_Information">2.2</linkHtml>)<br/>
                           </item>
                           <item>INGREZZA SPRINKLE may be opened and sprinkled over soft food (do not use milk or drinking water). INGREZZA SPRINKLE may be swallowed whole with water. Do not crush or chew. (<linkHtml href="#_2_2_Administrative_Information">2.2</linkHtml>)<br/>
                           </item>
                           <item>The recommended dosage for patients with moderate or severe hepatic impairment is 40 mg once daily. (<linkHtml href="#_2_2_Dosage_Recommendations">2.3</linkHtml>)<br/>
                           </item>
                           <item>The recommended dosage for known CYP2D6 poor metabolizers is 40 mg once daily. (<linkHtml href="#_2_3_Dosage_Recommendations">2.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_2_1_Dosing_and">
                     <id root="1683c9ad-264c-45c7-9189-1cdd91e22e59"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1 </content>
                        <content styleCode="bold">Recommended</content>
                        <content styleCode="bold"> </content>
                        <content styleCode="bold">Dosage </content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Tardive Dyskinesia</content>
                        </paragraph>
                        <paragraph>The initial dosage for INGREZZA and INGREZZA SPRINKLE is 40 mg once daily. After one week, increase the dose to the recommended dosage of 80 mg once daily.  A dosage of 40 mg or 60 mg once daily may be considered depending on response and tolerability. </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="underline">Chorea Associated with Huntington</content>
                              <content styleCode="underline">’s</content>
                              <content styleCode="underline"> Disease</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The initial dosage for INGREZZA and INGREZZA SPRINKLE is 40 mg once daily. Increase the dose in 20 mg increments every two weeks to the recommended dosage of 80 mg once daily. A dosage of 40 mg or 60 mg once daily may be considered depending on response and tolerability. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_2_Administrative_Information">
                     <id root="5a152c62-a7b7-4380-9a81-51a382460da0"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2 Administrative Information</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Administer INGREZZA and INGREZZA SPRINKLE orally with or without food <content styleCode="italics">[see Clinical Pharmacology (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="underline">Administration Information for INGREZZA SPRINKLE</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">• Open INGREZZA SPRINKLE and sprinkle the entire contents of the capsule over a bowl containing a small amount (1 tablespoonful) of soft food such as applesauce, yogurt, or pudding. Do not sprinkle the contents of the capsule into milk or drinking water. Stir the contents of the capsule into the soft food with the tablespoon and swallow the drug/food mixture immediately. If necessary, the mixture can be stored for up to 2 hours at room temperature. Discard of any unused portion after 2 hours. Following administration of the drug/food mixture, drink a glass (e.g., 240 mL) of water.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Do not administer INGREZZA SPRINKLE via nasogastric, gastrostomy, or other enteral tubes because it may cause obstruction of enteral tubes.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">• INGREZZA SPRINKLE may be swallowed whole with water. Do not crush or chew INGREZZA SPRINKLE.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_2_Dosage_Recommendations">
                     <id root="bbe3aa78-d1aa-4eeb-8800-9398f0fda796"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.</content>
                        <content styleCode="bold">3 </content>
                        <content styleCode="bold">Dosage Recommendations for Patients with Hepatic Impairment</content>
                     </title>
                     <text>
                        <paragraph>The recommended dosage for patients with moderate or severe hepatic impairment (Child-Pugh score 7 to 15) is INGREZZA or INGREZZA SPRINKLE 40 mg once daily <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_7_Hepatic_Impairment">8.7</linkHtml>
                           </content>
                           <content styleCode="italics">), Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_3_Dosage_Recommendations">
                     <id root="cef9317a-1db6-421d-95e4-5e760156b624"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.</content>
                        <content styleCode="bold">4 </content>
                        <content styleCode="bold">Dosage Recommendations for Known CYP2D6 Poor Metabolizers</content>
                     </title>
                     <text>
                        <paragraph>The recommended dosage for known CYP2D6 poor metabolizers is INGREZZA or INGREZZA SPRINKLE 40 mg once daily <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_6_CYP2D6_Poor">8.6</linkHtml>
                           </content>
                           <content styleCode="italics">), Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_5_Pharmacogenomics">12.5</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_4_Dosage_Recommendations">
                     <id root="7538a003-4021-435b-b3f0-271032ed0bd7"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.</content>
                        <content styleCode="bold">5 </content>
                        <content styleCode="bold">Dosage Recommendations for Concomitant Use with Strong CYP3A4 Inducers and Strong CYP3A4 or CYP2D6 Inhibitors</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Coadministration with Strong CYP3A4 Inducers</content>
                        </paragraph>
                        <paragraph>Concomitant use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE is not recommended <content styleCode="italics">[</content>
                           <content styleCode="italics">see Drug Interactions </content>
                           <content styleCode="italics">(</content>
                           <content styleCode="italics">
                              <linkHtml href="#_7_1_Drugs_Having">7.1</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Coadministration with Strong CYP3A4 Inhibitors</content>
                        </paragraph>
                        <paragraph>The recommended dosage for patients receiving strong CYP3A4 inhibitors is INGREZZA or INGREZZA SPRINKLE 40 mg once daily <content styleCode="italics">[see Drug Interactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_7_1_Drugs_Having">7.1</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Coadministration with Strong CYP2D6 Inhibitors</content>
                        </paragraph>
                        <paragraph>The recommended dosage for patients receiving strong CYP2D6 inhibitors is INGREZZA or INGREZZA SPRINKLE 40 mg once daily <content styleCode="italics">[see Drug Interactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_7_1_Drugs_Having">7.1</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_3_DOSAGE_FORMS">
               <id root="a215b06b-84ec-48da-ba94-fd36a26a600a"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3 </content>
                  <content styleCode="bold">DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">INGREZZA</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>40 mg capsule: white opaque body and purple cap, printed with ‘VBZ’ and ‘40’ in black ink. Each capsule contains 40 mg valbenazine.<br/>
                     </item>
                     <item>60 mg capsule: dark red opaque body and purple cap, printed with ‘VBZ’ and ‘60’ in black ink. Each capsule contains 60 mg valbenazine.<br/>
                     </item>
                     <item>80 mg capsule: purple opaque body and cap, printed with ‘VBZ’ and ‘80’ in black ink. Each capsule contains 80 mg valbenazine.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">INGREZZA SPRINKLE</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>40 mg capsule: pearl white opaque cap and body, printed with a band, directional arrows, and “VBZ 40” in black ink on both the cap and body. Each capsule contains 40 mg valbenazine.<br/>
                     </item>
                     <item>60 mg capsule: pearl white opaque cap and body, printed with a band, directional arrows, and “VBZ 60” in dark red ink on both the cap and body. Each capsule contains 60 mg valbenazine.<br/>
                     </item>
                     <item>80 mg capsule: pearl white opaque cap and body, printed with a band, directional arrows, and “VBZ 80” in purple ink on both the cap and body. Each capsule contains 80 mg valbenazine.</item>
                  </list>
               </text>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>INGREZZA capsules: 40 mg, 60 mg and 80 mg. (<linkHtml href="#_3_DOSAGE_FORMS">3</linkHtml>)</paragraph>
                        <paragraph>INGREZZA SPRINKLE capsules: 40 mg, 60 mg, and 80 mg. (<linkHtml href="#_3_DOSAGE_FORMS">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_4_CONTRAINDICATIONS">
               <id root="248080e9-a024-4dcd-8ce9-b26d0e7c3079"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4 </content>
                  <content styleCode="bold">CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>INGREZZA and INGREZZA SPRINKLE are contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA or INGREZZA SPRINKLE. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported with use of INGREZZA <content styleCode="italics">[see </content>
                     <content styleCode="italics">Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_2_Hypersensitivity_Reactions">5.2</linkHtml>
                     </content>
                     <content styleCode="italics">) and </content>
                     <content styleCode="italics">Adverse Reactions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_6_2_Postmarketing_Experience">6.2</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Known hypersensitivity to valbenazine or any components of INGREZZA or INGREZZA SPRINKLE. (<linkHtml href="#_4_CONTRAINDICATIONS">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="ff40aada-2dc7-458c-8eb5-2bfe9a51e155"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5 </content>
                  <content styleCode="bold">WARNINGS AND PRECAUTIONS</content>
               </title>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Depression and suicidal ideation and behavior in patients with Huntington’s disease. (<linkHtml href="#_5_1_Depression_and">5.1</linkHtml>)<br/>
                           </item>
                           <item>Hypersensitivity, including angioedema may occur. Discontinue if this occurs. (<linkHtml href="#_5_2_Hypersensitivity_Reactions">5.2</linkHtml>)<br/>
                           </item>
                           <item>Somnolence/sedation: May impair patient’s ability to drive or operate hazardous machinery. (<linkHtml href="#_5_3_Somnolence_and">5.3</linkHtml>)<br/>
                           </item>
                           <item>QT Prolongation:  May cause an increase in QT interval.  Avoid use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. (<linkHtml href="#_5_4_QT_Prolongation">5.4</linkHtml>)<br/>
                           </item>
                           <item>Neuroleptic Malignant Syndrome (NMS): Discontinue if this occurs. (<linkHtml href="#_5_5_Neuroleptic_Malignant">5.5</linkHtml>)<br/>
                           </item>
                           <item>Parkinsonism: Cases of parkinson-like symptoms, some of which were severe, have been reported in the postmarketing period. Reduce the dose or discontinue INGREZZA or INGREZZA SPRINKLE treatment in patients who develop clinically significant parkinson-like signs or symptoms. (<linkHtml href="#_5_6_Parkinsonism">5.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_5_1_Depression_and">
                     <id root="bd456879-0adb-410b-80a5-4971251e9e71"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1 </content>
                        <content styleCode="bold">Depression and Suicidal Ideation and Behavior in Patients with Huntington’s Disease</content>
                        <content styleCode="bold"> </content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Patients with Huntington’s disease are at increased risk for depression, and suicidal ideation or behaviors. VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk for suicidal ideation and behaviors in patients with Huntington’s disease. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">In a 14-week, double-blind, placebo-controlled trial <content styleCode="italics">[see Clinical Studies (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#_14_2_Chorea_Associated">14.2</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>, depression or depressed mood was reported in 4.7% of patients taking INGREZZA compared to 1.6% of patients who received placebo, and no patients taking INGREZZA reported suicidal ideation or behavior compared to 1 patient (1.6%) who received placebo. Patients with significant risk for suicidal behavior or with unstable psychiatric symptoms were excluded from this trial. Suicidal ideation (9 subjects; 7.2%) and suicide attempts (3 subjects; 2.4%) were reported in the longer open-label extension trial (N=125). </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">When considering the use of INGREZZA or INGREZZA SPRINKLE, the risk of suicidal ideation and behaviors must be balanced against the need for treatment of chorea. All patients treated with INGREZZA and INGREZZA SPRINKLE should be observed for new or worsening depression, suicidal ideation or behaviors. If any of these reactions occur and do not resolve, consider discontinuing treatment with INGREZZA or INGREZZA SPRINKLE.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_2_Hypersensitivity_Reactions">
                     <id root="287aafd0-8d81-41b6-bd4f-fda38a2d82bc"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.2 </content>
                        <content styleCode="bold">Hypersensitivity Reactions</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Hypersensitivity reactions, including cases of angioedema involving the larynx, glottis, lips, and eyelids, have been reported in the postmarketing setting in patients after taking the first or subsequent doses of INGREZZA <content styleCode="italics">[see Adverse Reactions (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#_6_2_Postmarketing_Experience">6.2</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>. A case of angioedema involving the lips and face, with rash and shortness of breath was reported in a patient with Huntington’s disease taking INGREZZA during a clinical study. Urticaria and rash were also reported during a clinical study in patients with Huntington’s disease. Angioedema associated with laryngeal edema can be fatal. If any of these reactions occur, discontinue INGREZZA or INGREZZA SPRINKLE.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_3_Somnolence_and">
                     <id root="ec3f9287-4ee5-487c-86cc-2fba8631d63f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.</content>
                        <content styleCode="bold">3 </content>
                        <content styleCode="bold">Somnolence </content>
                        <content styleCode="bold">and Sedation</content>
                     </title>
                     <text>
                        <paragraph>INGREZZA and INGREZZA SPRINKLE can cause somnolence and sedation, which was the most common adverse reaction in placebo-controlled trials with INGREZZA <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA or INGREZZA SPRINKLE<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_4_QT_Prolongation">
                     <id root="299e6eef-f055-4db8-8891-16916857921e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.</content>
                        <content styleCode="bold">4 </content>
                        <content styleCode="bold">QT Prolongation</content>
                     </title>
                     <text>
                        <paragraph>INGREZZA and INGREZZA SPRINKLE may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_2_Pharmacodynamics">12.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.  For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. For patients taking a strong CYP3A4 inhibitor, reduce the dose of INGREZZA or INGREZZA SPRINKLE to 40 mg once daily <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_3_Dosage_Recommendations">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_4_Dosage_Recommendations">2.5</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content> INGREZZA and INGREZZA SPRINKLE should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval.  For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_5_Neuroleptic_Malignant">
                     <id root="1528f17c-9c9e-48ce-966b-d7e709aa53f2"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.5 </content>
                        <content styleCode="bold">Neuroleptic Malignant Syndrome (NMS</content>
                        <content styleCode="bold">)</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. In the postmarketing setting, NMS has been reported in patients taking VMAT2 inhibitors, including INGREZZA. Clinicians should be alerted to the signs and symptoms associated with NMS. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria, rhabdomyolysis, and acute renal failure. The diagnosis of NMS can be complicated; other serious medical illness (e.g., pneumonia, systemic infection) and untreated or inadequately treated extrapyramidal disorders can present with similar signs and symptoms. Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The management of NMS should include (1) immediate discontinuation of INGREZZA or INGREZZA SPRINKLE; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Recurrence of NMS has been reported with resumption of drug therapy. If treatment with INGREZZA or INGREZZA SPRINKLE is needed after recovery from NMS, patients should be monitored for signs of recurrence.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_6_Parkinsonism">
                     <id root="1e5f5f3f-8012-4963-a8fc-d7fcc11b97b6"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.</content>
                        <content styleCode="bold">6 </content>
                        <content styleCode="bold">Parkinsonism</content>
                     </title>
                     <text>
                        <paragraph>INGREZZA and INGREZZA SPRINKLE may cause parkinsonism. Parkinsonism has also been observed with other VMAT2 inhibitors. In the 3 placebo-controlled clinical studies in patients with tardive dyskinesia, the incidence of parkinson-like adverse events was 3% of patients treated with INGREZZA and &lt;1% of placebo-treated patients.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">In a placebo-controlled clinical study in patients with chorea associated with Huntington’s disease, the incidence of parkinson-like adverse events was 4.7% in patients treated with INGREZZA and 0% in placebo-treated patients. Because rigidity can develop as part of the underlying disease process in Huntington’s disease, it may be difficult to distinguish between potential drug-induced parkinsonism and progression of underlying Huntington’s disease. Drug-induced parkinsonism has the potential to cause more functional disability than untreated chorea for some patients with Huntington’s disease.</content>
                        </paragraph>
                        <paragraph>Postmarketing safety reports have described parkinson-like symptoms in patients taking INGREZZA for tardive dyskinesia, some of which were severe and required hospitalization. In most cases, severe parkinsonism occurred within the first two weeks after starting or increasing the dose of INGREZZA. Associated symptoms have included falls, gait disturbances, tremor, drooling and hypokinesia. In cases in which follow-up clinical information was available, parkinson-like symptoms were reported to resolve following discontinuation of INGREZZA therapy. </paragraph>
                        <paragraph>Reduce the dose or discontinue INGREZZA or INGREZZA SPRINKLE treatment in patients who develop clinically significant parkinson-like signs or symptoms.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="e9399b59-9dff-46cf-ab29-b50026526558"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6 </content>
                  <content styleCode="bold">ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are discussed in more detail in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Depression and Suicidal Ideation and Behavior in Patients with Huntington’s Disease <content styleCode="italics">[see </content>
                        <content styleCode="italics">
                           <linkHtml href="#BoxedWarning">Boxed Warning</linkHtml>
                        </content>
                        <content styleCode="italics"> and Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_1_Depression_and">5.1</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Hypersensitivity Reactions <content styleCode="italics">[see Contraindications (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_4_CONTRAINDICATIONS">4</linkHtml>
                        </content>
                        <content styleCode="italics">)</content>
                        <content styleCode="italics"> </content>
                        <content styleCode="italics">and </content>
                        <content styleCode="italics">Warnings and Precautions</content>
                        <content styleCode="italics"> (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_2_Hypersensitivity_Reactions">5.2</linkHtml>
                        </content>
                        <content styleCode="italics">)</content>
                        <content styleCode="italics">]</content>
                        <br/>
                     </item>
                     <item>Somnolence and Sedation <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_3_Somnolence_and">5.3</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>QT Prolongation <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_4_QT_Prolongation">5.4</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Neuroleptic Malignant Syndrome (NMS) <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_5_Neuroleptic_Malignant">5.5</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Parkinsonism <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_6_Parkinsonism">5.6</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reaction (≥5% and twice the rate of placebo): <br/>- Tardive dyskinesia: somnolence. (<linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>) <br/>- Chorea associated with Huntington’s disease: somnolence/lethargy/sedation, urticaria, rash, insomnia. (<linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact Neurocrine Biosciences, Inc. at 877-641-3461 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_6_1_Clinical_Trials">
                     <id root="da5ace1a-0125-4bb5-a132-bbf803037e91"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90374-0" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.1 </content>
                        <content styleCode="bold">Clinical Trials Experience</content>
                     </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety of INGREZZA SPRINKLE has been established from adequate and well-controlled studies of INGREZZA <content styleCode="italics">[see Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_14_CLINICAL_STUDIES">14</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Below is a display of the adverse reactions of INGREZZA in these adequate and well-controlled studies.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Tardive Dyskinesia</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics underline">Variable and Fixed Dose Placebo-Controlled Trial Experience</content>
                        </paragraph>
                        <paragraph>The safety of INGREZZA was evaluated in 3 placebo-controlled studies, each 6 weeks in duration (fixed dose, dose escalation, dose reduction), including 445 patients. Patients were 26 to 84 years of age with moderate to severe tardive dyskinesia and had concurrent diagnoses of mood disorder (27%) or schizophrenia/ schizoaffective disorder (72%). The mean age was 56 years. Patients were 57% Caucasian, 39% African-American, and 4% other. With respect to ethnicity, 28% were Hispanic or Latino. All subjects continued previous stable regimens of antipsychotics; 85% and 27% of subjects, respectively, were taking atypical and typical antipsychotic medications at study entry.  </paragraph>
                        <paragraph>
                           <content styleCode="italics">Adverse Reactions Leading to Discontinuation of Treatment</content>  </paragraph>
                        <paragraph>A total of 3% of INGREZZA-treated patients and 2% of placebo-treated patients discontinued because of adverse reactions.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Common Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Adverse reactions that occurred in the 3 placebo-controlled studies at an incidence of ≥2% and greater than placebo are presented in <linkHtml href="#Table1">Table 1</linkHtml>. </paragraph>
                        <table ID="Table1">
                           <caption>Table 1: 
		     
	Adverse Reactions in 3 Placebo-Controlled Studies of 6-week Treatment Duration Reported at ≥2% and &gt;Placebo – Tardive Dyskinesia</caption>
                           <col width="408"/>
                           <col width="153"/>
                           <col width="153"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Adverse Reaction</content>
                                    <content styleCode="bold">
                                       <sup>1</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">INGREZZA</content>
                                    <content styleCode="bold">
                                       <br/>(n=262) </content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <br/>(n=183) </content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">General Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Somnolence<br/>          (somnolence, fatigue, sedation)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Nervous System Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Anticholinergic effects</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5.4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule ">          (dry mouth, constipation, disturbance in attention, vision   </td>
                                 <td styleCode="Lrule Rrule " align="center"/>
                                 <td styleCode="Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule ">          blurred, urinary retention)</td>
                                 <td styleCode="Lrule Rrule " align="center"/>
                                 <td styleCode="Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Balance disorders/fall<br/>          (fall, gait disturbance, dizziness, balance disorder)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Headache</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3.4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.7</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Akathisia<br/>          (akathisia, restlessness)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Gastrointestinal Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Vomiting</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Nausea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Musculoskeletal Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Arthralgia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.5</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>1</sup> Within each adverse reaction category, the observed adverse reactions are listed in order of decreasing frequency.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Other Adverse Reactions Observed </content>
                           <content styleCode="italics">During the Premarketing Evaluation of INGREZZA</content>
                        </paragraph>
                        <paragraph>Other adverse reactions of ≥1% incidence and greater than placebo are shown below.  The following list does not include adverse reactions: 1) already listed in previous tables or elsewhere in the labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have clinically significant implications, or 5) which occurred at a rate equal to or less than placebo.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Endocrine Disorders: </content>blood glucose increased</paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders:</content> weight increased</paragraph>
                        <paragraph>
                           <content styleCode="italics">Infectious Disorders:</content> respiratory infections</paragraph>
                        <paragraph>
                           <content styleCode="italics">Neurologic Disorders:</content> drooling, dyskinesia, extrapyramidal symptoms (non-akathisia)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric Disorders:</content> anxiety, insomnia</paragraph>
                        <paragraph>During the tardive dyskinesia controlled trials, there was a dose-related increase in prolactin. Additionally, in these trials there was a dose-related increase in alkaline phosphatase and bilirubin, suggesting a potential risk for cholestasis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Chorea </content>
                           <content styleCode="underline">Associated </content>
                           <content styleCode="underline">with Huntington</content>
                           <content styleCode="underline">’s</content>
                           <content styleCode="underline"> Disease</content>
                        </paragraph>
                        <paragraph>The safety of INGREZZA was evaluated in a 14-week placebo-controlled study including 127 patients with chorea associated with Huntington’s disease. Patients were 25 to 75 years of age. The mean age was 54 years. Patients were 96% Caucasian, 1% African-American, 1% Asian, and 2% Other. With respect to ethnicity, 6% were Hispanic or Latino. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Adverse Reactions Leading to Discontinuation of Treatment</content>  </paragraph>
                        <paragraph>A total of 8% of INGREZZA-treated patients and 6% of placebo-treated patients discontinued because of adverse reactions.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Common Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Adverse reactions that occurred in the placebo-controlled study at an incidence of ≥4% and greater than placebo are presented in <linkHtml href="#Table2">Table 2</linkHtml>. </paragraph>
                        <table ID="Table2">
                           <caption>Table 2: 
		     
	Adverse Reactions in the Placebo-Controlled Study of 12-week Treatment Duration Reported at ≥4% and &gt;Placebo – Chorea Associated with Huntington’s Disease</caption>
                           <col width="360"/>
                           <col width="138"/>
                           <col width="217"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">INGREZZA </content>
                                    <content styleCode="bold">
                                       <br/>(n=64) </content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo </content>
                                    <content styleCode="bold">
                                       <br/>(n=63) </content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Nervous System Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Somnolence, lethargy, sedation</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">18.8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3.2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Akathisia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6.3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">General </content>
                                    <content styleCode="bold">Disorders </content>
                                    <content styleCode="bold">and </content>
                                    <content styleCode="bold">Administration Site Conditions</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Fatigue </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14.1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Skin and </content>
                                    <content styleCode="bold">Subcutaneous Tissue Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Urticaria</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9.4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Rash</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7.8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Gastrointestinal </content>
                                    <content styleCode="bold">Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Diarrhea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Nausea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Psychiatric </content>
                                    <content styleCode="bold">Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Insomnia, middle insomnia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6.3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Depression, depressed mood</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Musculoskeletal</content>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">D</content>
                                    <content styleCode="bold">isorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Back pain</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_6_2_Postmarketing_Experience">
                     <id root="c18efac6-8f1b-46bd-b3cb-021b37442fc5"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90375-7" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.2 </content>
                        <content styleCode="bold">Postmarketing Experience</content>
                     </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of INGREZZA that are not included in other sections of labeling. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System Disorders:</content> hypersensitivity reactions (including allergic dermatitis and pruritis) </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="6959b6b7-ff75-4f99-a8b7-8d238c9d15aa"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7 </content>
                  <content styleCode="bold">DRUG INTERACTIONS </content>
               </title>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Dose adjustments due to drug interactions (<linkHtml href="#_2_3_Dosage_Recommendations">2.4</linkHtml>, <linkHtml href="#_7_1_Drugs_Having">7.1</linkHtml>):</paragraph>
                        <table>
                           <col width="172"/>
                           <col width="168"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Factors</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Dose Adjustments for INGREZZA</content>
                                    <content styleCode="bold"> and INGREZZA SPRINKLE</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Use of MAOIs with INGREZZA or INGREZZA SPRINKLE</td>
                                 <td styleCode="Toprule Lrule Rrule ">Avoid concomitant use with MAOIs.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE</td>
                                 <td styleCode="Toprule Lrule Rrule ">Concomitant use is not recommended.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Use of strong CYP3A4 inhibitors with INGREZZA or INGREZZA SPRINKLE</td>
                                 <td styleCode="Toprule Lrule Rrule ">Recommended dosage is 40 mg once daily.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Use of strong CYP2D6 inhibitors with INGREZZA or INGREZZA SPRINKLE</td>
                                 <td styleCode="Toprule Lrule Rrule ">Recommended dosage is 40 mg once daily. </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_7_1_Drugs_Having">
                     <id root="4bdfc103-24df-4537-abc1-bf6efdbff1b9"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.1 </content>
                        <content styleCode="bold">Drugs Having Clinically Important Interactions with INGREZZA</content>
                        <content styleCode="bold"> and INGREZZA SPRINKLE</content>
                     </title>
                     <text>
                        <table>
                           <caption>Table 3:  
		     
	Clinically Significant Drug Interactions with INGREZZA and INGREZZA SPRINKLE</caption>
                           <col width="200"/>
                           <col width="462"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2">
                                    <content styleCode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">Clinical Implication:</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Concomitant use of INGREZZA or INGREZZA SPRINKLE with MAOIs may increase the concentration of monoamine neurotransmitters in synapses, potentially leading to increased risk of adverse reactions such as serotonin syndrome, or attenuated treatment effect of INGREZZA or INGREZZA SPRINKLE.  </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">Prevention or Management:</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Avoid concomitant use of INGREZZA or INGREZZA SPRINKLE with MAOIs, or within 14 days of discontinuing therapy with an MAOI.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2">
                                    <content styleCode="bold">Strong CYP3A4 Inhibitors</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">Clinical Implication:</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Concomitant use of INGREZZA or INGREZZA SPRINKLE with strong CYP3A4 inhibitors increased the exposure (C<sub>max</sub> and AUC) to valbenazine and its active metabolite compared with the use of INGREZZA or INGREZZA SPRINKLE alone <content styleCode="italics">[see Clinical Pharmacology (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                                    </content>
                                    <content styleCode="italics">)].</content> Increased exposure of valbenazine and its active metabolite may increase the risk of exposure-related adverse reactions <content styleCode="italics">[see Warnings and Precautions (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_5_4_QT_Prolongation">5.4</linkHtml>
                                    </content>
                                    <content styleCode="italics">)].</content>
                                    <content styleCode="italics"> </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">Prevention or Management:</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Reduce INGREZZA or INGREZZA SPRINKLE dose when INGREZZA or INGREZZA SPRINKLE is coadministered with a strong CYP3A4 inhibitor <content styleCode="italics">[see Dosage and Administration (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_2_4_Dosage_Recommendations">2.5</linkHtml>
                                    </content>
                                    <content styleCode="italics">)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2">
                                    <content styleCode="bold">Strong CYP2D6 Inhibitors</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">Clinical Implication:</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Concomitant use of INGREZZA or INGREZZA SPRINKLE with strong CYP2D6 inhibitors increased the exposure (C<sub>max</sub> and AUC) to valbenazine’s active metabolite compared with the use of INGREZZA or INGREZZA SPRINKLE alone <content styleCode="italics">[see Clinical Pharmacology (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                                    </content>
                                    <content styleCode="italics">, </content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_12_5_Pharmacogenomics">12.5</linkHtml>
                                    </content>
                                    <content styleCode="italics">)]</content>. Increased exposure of active metabolite may increase the risk of exposure-related adverse reactions <content styleCode="italics">[see Warnings and Precautions (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_5_4_QT_Prolongation">5.4</linkHtml>
                                    </content>
                                    <content styleCode="italics">)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">Prevention or Management:</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Reduce INGREZZA or INGREZZA SPRINKLE dose when INGREZZA or INGREZZA SPRINKLE is coadministered with a strong CYP2D6 inhibitor <content styleCode="italics">[see Dosage and Administration (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_2_4_Dosage_Recommendations">2.5</linkHtml>
                                    </content>
                                    <content styleCode="italics">)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2">
                                    <content styleCode="bold">Strong CYP3A4 Inducers</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">Clinical Implication:</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Concomitant use of INGREZZA or INGREZZA SPRINKLE with a strong CYP3A4 inducer decreased the exposure of valbenazine and its active metabolite compared to the use of INGREZZA or INGREZZA SPRINKLE alone. Reduced exposure of valbenazine and its active metabolite may reduce efficacy <content styleCode="italics">[see Clinical Pharmacology (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                                    </content>
                                    <content styleCode="italics">)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">Prevention or Management:</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Concomitant use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE is not recommended <content styleCode="italics">[see Dosage and Administration (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_2_4_Dosage_Recommendations">2.5</linkHtml>
                                    </content>
                                    <content styleCode="italics">)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2">
                                    <content styleCode="bold">Digoxin</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">Clinical Implication:</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Concomitant use of INGREZZA or INGREZZA SPRINKLE with digoxin increased digoxin levels because of inhibition of intestinal P-glycoprotein (P-gp)<content styleCode="italics"> [see Clinical Pharmacology (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                                    </content>
                                    <content styleCode="italics">)]</content>.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">Prevention or Management:</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Digoxin concentrations should be monitored when co-administering INGREZZA or INGREZZA SPRINKLE with digoxin.  Increased digoxin exposure may increase the risk of exposure-related adverse reactions. Dosage adjustment of digoxin may be necessary.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="ffc00087-65f0-4bb9-beab-1889eceb3429"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8 </content>
                  <content styleCode="bold">USE IN SPECIFIC POPULATIONS</content>
               </title>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Pregnancy:  May cause fetal harm. (<linkHtml href="#_8_1_Pregnancy">8.1</linkHtml>)<br/>
                           </item>
                           <item>Lactation:  Advise not to breastfeed. (<linkHtml href="#_8_2_Lactation">8.2</linkHtml>)</item>
                        </list>
                        <paragraph>
		     
	
		     
	
		     
	<content styleCode="bold">
		     
	</content>
                        </paragraph>
                        <paragraph>
		     
	
		     
	
		     
	
		     
	<content styleCode="bold"/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_8_1_Pregnancy">
                     <id root="59d53729-df80-4cae-bfed-3b01e87f9d84"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1 </content>
                        <content styleCode="bold">Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>The limited available data on INGREZZA or INGREZZA SPRINKLE use in pregnant women are insufficient to inform a drug-associated risk. In animal reproductive studies, no malformations were observed when valbenazine was administered orally to rats and rabbits during the period of organogenesis at doses up to 1.8 or 24 times, respectively, the maximum recommended human dose (MRHD) of 80 mg/day based on mg/m<sup>2</sup> body surface area. However, administration of valbenazine to pregnant rats during organogenesis through lactation produced an increase in the number of stillborn pups and postnatal pup mortalities at doses &lt;1 times the MRHD based on mg/m<sup>2 </sup>
                           <content styleCode="italics">[see </content>
                           <content styleCode="italics">Data</content>
                           <content styleCode="italics">].</content> Advise a pregnant woman of the potential risk to a fetus.  </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage in the U.S. general population is 2 to 4% and 15 to 20% of clinically recognized pregnancies, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                           <content styleCode="underline"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data </content>
                        </paragraph>
                        <paragraph>Valbenazine was administered orally to pregnant rats during the period of organogenesis at 1, 5, and 15 mg/kg/day, which are approximately 0.1, 0.6, and 2 times the MRHD of 80 mg/day based on mg/m<sup>2</sup> body surface area. Valbenazine produced a significant decrease in maternal body weight gain at 0.6 and 2 times the MRHD of 80 mg/day based on mg/m<sup>2</sup>. No adverse embryo fetal effects were produced when valbenazine was administered at doses up to 2 times the MRHD of 80 mg/day based on mg/m<sup>2</sup>. </paragraph>
                        <paragraph>Valbenazine was administered orally to pregnant rabbits during the period of organogenesis at 20, 50, and 100 mg/kg/day, which are approximately 5, 12, and 24 times the MRHD of 80 mg/day based on mg/m<sup>2</sup>. No malformations were observed at doses up to 24 times the MRHD of 80 mg/day based on mg/m<sup>2</sup>. However, valbenazine produced a delay in fetal development (decreased fetal weights and delayed ossification) at 24 times the MRHD of 80 mg/day based on mg/m<sup>2</sup>, likely secondary to maternal toxicity (decreased food intake and loss in body weight).</paragraph>
                        <paragraph>Valbenazine was administered orally to pregnant rats during the period of organogenesis through lactation (day 7 of gestation through day 20 postpartum) at 1, 3, and 10 mg/kg/day, which are approximately 0.1, 0.4, and 1.2 times the MRHD of 80 mg/day based on mg/m<sup>2</sup>. Valbenazine produced an increase in the incidence of stillbirths and postnatal pup mortality at 0.4 and 1.2 times the MRHD of 80 mg/day based on mg/m<sup>2</sup>. Valbenazine did not affect neurobehavioral function including learning and memory and had no effect on sexual maturation at doses &lt;1 times the MRHD of 80 mg/day based on mg/m<sup>2 </sup>(because of death in the majority of the high dose group (1.2 times the MRHD), these parameters were not assessed in this group).</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_2_Lactation">
                     <id root="bb8b6759-5a55-464e-a425-81e86f090606"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77290-5" displayName="LACTATION SECTION"/>
                     <title>
                        <content styleCode="bold">8.2 </content>
                        <content styleCode="bold">Lactation </content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>There is no information regarding the presence of valbenazine or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. Valbenazine and its metabolites have been detected in rat milk at concentrations higher than in plasma following oral administration of valbenazine at doses 0.1 to 1.2 times the MRHD based on mg/m<sup>2</sup>. Based on animal findings of increased perinatal mortality in exposed fetuses and pups, advise a woman not to breastfeed during treatment with INGREZZA or INGREZZA SPRINKLE and for 5 days after the final dose.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="40b808de-c1cf-42f9-8d0b-ce9d50691e4d"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4 </content>
                        <content styleCode="bold">Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>Safety and effectiveness of INGREZZA and INGREZZA SPRINKLE have not been established in pediatric patients.  </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="e2ab6c50-730b-4ab8-8eeb-f3df7e4b1872"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5 </content>
                        <content styleCode="bold">Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>No dose adjustment of INGREZZA or INGREZZA SPRINKLE is required for elderly patients.  </paragraph>
                        <paragraph>
                           <content styleCode="underline">Tardive Dyskinesia</content>
                        </paragraph>
                        <paragraph>In 3 randomized, placebo-controlled studies of INGREZZA in patients with tardive dyskinesia, 16% of patients were 65 years and older. The safety and effectiveness were similar in patients older than 65 years compared to younger patients.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Huntington’s Disease</content>
                        </paragraph>
                        <paragraph>In the randomized, placebo-controlled study of INGREZZA in 127 patients with chorea associated with Huntington’s disease, 15% were 65 years and older. This study did not include sufficient numbers of subjects aged 65 and older to determine whether they responded differently from younger subjects <content styleCode="italics">[see Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_14_2_Chorea_Associated">14.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_6_CYP2D6_Poor">
                     <id root="4b1942fc-976e-4c34-8081-9e50eb436050"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.6 </content>
                        <content styleCode="bold">CYP2D6 Poor Metabolizers</content>
                     </title>
                     <text>
                        <paragraph>Dosage reduction of INGREZZA and INGREZZA SPRINKLE is recommended for known CYP2D6 poor metabolizers <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_3_Dosage_Recommendations">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Increased exposure (C<sub>max</sub> and AUC) to valbenazine’s active metabolite was observed in CYP2D6 poor metabolizers. Increased exposure of active metabolite may increase the risk of exposure-related adverse reactions <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_5_Pharmacogenomics">12.5</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>
                           <content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_7_Hepatic_Impairment">
                     <id root="34c03f63-a5ff-4551-b782-8bad9d3d2ab7"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.7 </content>
                        <content styleCode="bold">Hepatic Impairment</content>
                     </title>
                     <text>
                        <paragraph>Dosage reduction of INGREZZA and INGREZZA SPRINKLE is recommended for patients with moderate or severe hepatic impairment <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_2_Dosage_Recommendations">2.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>
                           <content styleCode="italics">.</content>  Patients with moderate to severe hepatic impairment (Child-Pugh score 7 to 15) had higher exposure of valbenazine and its active metabolite than patients with normal hepatic function <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="5e363f5f-776f-4751-a033-dc612093464a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.8</content>
                        <content styleCode="bold"> </content>
                        <content styleCode="bold">Renal Impairment</content>
                     </title>
                     <text>
                        <paragraph>Dosage adjustment is not necessary for patients with mild, moderate, or severe renal impairment.  INGREZZA and INGREZZA SPRINKLE do not undergo primary renal clearance. <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="4141c312-91e0-4dbc-baef-fb20264528ae"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34088-5" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">10 </content>
                  <content styleCode="bold">OVERDOSAGE</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Human Experience</content>
                  </paragraph>
                  <paragraph>The pre-marketing clinical trials involving INGREZZA in approximately 850 subjects do not provide information regarding symptoms with overdose.  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Management of Overdosage</content>
                  </paragraph>
                  <paragraph>No specific antidotes for INGREZZA or INGREZZA SPRINKLE are known.  In managing overdose, provide supportive care, including close medical supervision and monitoring, and consider the possibility of multiple drug involvement. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.</paragraph>
               </text>
               <effectiveTime value="20240430"/>
            </section>
         </component>
         <component>
            <section>
               <id root="32f65dd7-c1be-4e74-b52e-569b059a9360"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11 </content>
                  <content styleCode="bold">DESCRIPTION </content>
               </title>
               <text>
                  <paragraph>INGREZZA and INGREZZA SPRINKLE contains valbenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, present as valbenazine tosylate salt, with the chemical name, L-Valine, (<content styleCode="italics">2R,3R</content>,11b<content styleCode="italics">R</content>)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2<content styleCode="italics">H</content>-benzo[<content styleCode="italics">a</content>]quinolizin-2-yl ester, 4-methylbenzenesulfonate (1:2).  Valbenazine tosylate is slightly soluble in water.  Its molecular formula is C<sub>38</sub>H<sub>54</sub>N<sub>2</sub>O<sub>10</sub>S<sub>2</sub>, and its molecular weight is <br/>762.97 g/mol (ditosylate salt) with the following structure:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000001"/>
                  </paragraph>
                  <paragraph>The molecular formula of valbenazine free base is C<sub>24</sub>H<sub>38</sub>N<sub>2</sub>O<sub>4 </sub>and its molecular weight is 418.57.</paragraph>
                  <paragraph>INGREZZA is intended for oral administration only. Each capsule contains 73 mg, 109 mg or 146 mg of valbenazine tosylate equivalent to 40 mg, 60 mg or 80 mg of valbenazine free base, respectively. The capsules contain the following inactive ingredients: hypromellose, isomalt, magnesium stearate, pregelatinized starch, and silicified microcrystalline cellulose. The capsule shells contain candurin silver fine, FD&amp;C Blue#1, FD&amp;C Red#40, and gelatin. </paragraph>
                  <paragraph>INGREZZA SPRINKLE is intended for oral administration. Each capsule contains granules consisting of 73 mg, 109 mg or 146 mg of valbenazine tosylate equivalent to 40 mg, 60 mg or 80 mg of valbenazine free base, respectively. The oral granules contain the following inactive ingredients: silicified microcrystalline cellulose, isomalt, pregelatinized maize starch, hypromellose, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc in hard gelatin capsules (contains gelatin and candurin silver fine).</paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <observationMedia ID="MM03000001">
                     <text>INGREZZA contains valbenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, present as valbenazine tosylate salt, with the chemical name, L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester, 4-methylbenzenesulfonate (1:2).  Valbenazine tosylate is slightly soluble in water.  Its molecular formula is C38H54N2O10S2, and its molecular weight is 762.97 g/mol (ditosylate salt) with the following structure:</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="62023c66-8203-42d4-8246-c9be814aabc6"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12 </content>
                  <content styleCode="bold">CLINICAL PHARMACOLOGY</content>
               </title>
               <effectiveTime value="20240430"/>
               <component>
                  <observationMedia ID="MM03000002">
                     <text>Figure 1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000003">
                     <text>Figure 2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000004">
                     <text>Figure 3</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <section>
                     <id root="ca12a4b3-1122-4fee-a565-db6c957889fe"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1 </content>
                        <content styleCode="bold">Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>The mechanism of action of valbenazine for the treatment of tardive dyskinesia and chorea in patients with Huntington’s disease is unclear, but is thought to be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.  </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_12_2_Pharmacodynamics">
                     <id root="a365626f-797b-4b04-9317-5b4f5ac0b952"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43681-6" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.2 </content>
                        <content styleCode="bold">Pharmacodynamics</content>
                     </title>
                     <text>
                        <paragraph>Valbenazine inhibits human VMAT2 (Ki ~ 150 nM) with no appreciable binding affinity for VMAT1 (Ki &gt; 10 µM). Valbenazine is converted to the active metabolite [+]-α-dihydrotetrabenazine ([+]-α-HTBZ). <br/>[+]-α-HTBZ also binds with relatively high affinity to human VMAT2 (Ki ~ 3 nM). Valbenazine and [+]-α-HTBZ have no appreciable binding affinity (Ki &gt; 5000 nM) for dopaminergic (including D2), serotonergic (including 5HT2B), adrenergic, histaminergic or muscarinic receptors. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>INGREZZA and INGREZZA SPRINKLE may cause an increase in the corrected QT interval in patients who are CYP2D6 poor metabolizers or who are taking a strong CYP2D6 or CYP3A4 inhibitor. An exposure-response analysis of clinical data from two healthy volunteer studies revealed increased QTc interval with higher plasma concentrations of the active metabolite. Based on this model, patients taking an INGREZZA 60 mg or 80 mg dose with increased exposure to the metabolite (e.g., being a CYP2D6 poor metabolizer) may have a mean (upper bound of double-sided 90% CI) QT prolongation of 9.6 (12.0) msec or 11.7 (14.7) msec, respectively as compared to otherwise healthy volunteers given INGREZZA, who had a respective mean (upper bound of double-sided 90% CI) QT prolongation of 5.3 (6.7) msec or 6.7 (8.4) msec <content styleCode="italics">[see Warnings and Precautions </content>
                           <content styleCode="italics">(</content>
                           <content styleCode="italics">
                              <linkHtml href="#_5_4_QT_Prolongation">5.4</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_12_3_Pharmacokinetics">
                     <id root="6ae92ed5-38cc-4ad1-aae2-ebf7f90c4e51"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3 </content>
                        <content styleCode="bold">Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>Valbenazine and its active metabolite ([+]-α-HTBZ) demonstrate approximate proportional increases for the area under the plasma concentration versus time curve (AUC) and maximum plasma concentration (C<sub>max</sub>) after single oral doses from 40 mg to 300 mg (i.e., 50% to 375% of the recommended treatment dose). </paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">INGREZZA</content>
                        </paragraph>
                        <paragraph>Following oral administration of INGREZZA, the time to reach maximum valbenazine plasma concentration (t<sub>max</sub>) ranges from 0.5 to 1.0 hours. Valbenazine reaches steady state plasma concentrations within 1 week. The absolute oral bioavailability of valbenazine is approximately 49%. [+]-α-HTBZ gradually forms and reaches C<sub>max</sub> 4 to 8 hours after administration of INGREZZA. </paragraph>
                        <paragraph>INGREZZA SPRINKLE</paragraph>
                        <paragraph>Following administration of 80 mg INGREZZA SPRINKLE orally as sprinkle on applesauce, the geometric mean peak plasma concentration (C<sub>max</sub>) of valbenazine was 512 ng/mL, area under the plasma concentration-time curve (AUC<sub>inf</sub>) was 5,600 ng*hr/mL and the median time to reach C<sub>max</sub> (T<sub>max</sub>) was 1.5 hours. For the [+]-α-HTBZ metabolite, the geometric mean C<sub>max</sub> was 23 ng/mL, AUC<sub>inf</sub> was 739 ng*hr/mL and the median T<sub>max</sub> was 6 hours.</paragraph>
                        <paragraph>Following oral administration of 80 mg INGREZZA, the geometric mean C<sub>max</sub>, AUC<sub>inf</sub> and median T<sub>max</sub> of valbenazine were 744 ng/mL, 6,419 ng*hr/mL and 0.5 hour, respectively. For the [+]-α-HTBZ metabolite, the geometric mean C<sub>max</sub> was 26 ng/mL, AUC<sub>inf</sub> was 859 ng*hr/mL and the median T<sub>max</sub> was 6 hours.</paragraph>
                        <paragraph>When 80 mg INGREZZA SPRINKLE capsules were swallowed whole with water, the geometric mean valbenazine C<sub>max</sub>, AUC<sub>inf</sub> and median T<sub>max</sub> were 685 ng/mL, 5,981 ng*hr/mL and 1 hour, respectively.  For the [+]-α-HTBZ metabolite, the geometric mean C<sub>max</sub> was 23 ng/mL, AUC<sub>inf </sub>was 772 ng*hr/mL and the median T<sub>max</sub> was 6 hours.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food</content>
                        </paragraph>
                        <paragraph>INGREZZA</paragraph>
                        <paragraph>Ingestion of a high-fat meal decreases valbenazine C<sub>max</sub> by approximately 47% and AUC by approximately 13%. [+]-α-HTBZ C<sub>max</sub> and AUC are unaffected. </paragraph>
                        <paragraph>INGREZZA SPRINKLE</paragraph>
                        <paragraph>Ingestion of a high-fat meal decreases valbenazine C<sub>max</sub> by approximately 15% and did not have an appreciable effect on AUC.  [+]-α-HTBZ C<sub>max</sub> and AUC are unaffected.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The plasma protein binding of valbenazine and [+]-α-HTBZ are greater than 99% and approximately 64%, respectively. The mean steady state volume of distribution of valbenazine is 92 L.</paragraph>
                        <paragraph>Nonclinical data in Long-Evans rats show that valbenazine can bind to melanin-containing structures of the eye such as the uveal tract.  The relevance of this observation to clinical use of INGREZZA or INGREZZA SPRINKLE is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>Valbenazine has a mean total plasma systemic clearance value of 7.2 L/hr.  Valbenazine and [+]-α-HTBZ have half-lives of 15 to 22 hours.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Valbenazine is extensively metabolized after oral administration by hydrolysis of the valine ester to form the active metabolite ([+]-α-HTBZ) and by oxidative metabolism, primarily by CYP3A4/5, to form mono-oxidized valbenazine and other minor metabolites.  [+]-α-HTBZ appears to be further metabolized in part by CYP2D6. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Following the administration of a single 50-mg oral dose of radiolabeled C-valbenazine (i.e., ~63% of the recommended treatment dose), approximately 60% and 30% of the administered radioactivity was recovered in the urine and feces, respectively.  Less than 2% was excreted as unchanged valbenazine or [+]-α-HTBZ in either urine or feces.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific</content>
                           <content styleCode="underline"> </content>
                           <content styleCode="underline">Populations</content>
                        </paragraph>
                        <paragraph>Exposures of valbenazine in patients with hepatic and severe renal impairment are summarized in <linkHtml href="#Figure1">Figure 1</linkHtml>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1:</content>
                           <content styleCode="bold">
		     
	Effects of Hepatic </content>
                           <content styleCode="bold">and Severe Renal </content>
                           <content styleCode="bold">Impairment on Valbenazine Pharmacokinetics</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure1" referencedObject="MM03000002"/>
                        </paragraph>
                        <paragraph> AUC<sub>inf</sub>=area under the plasma concentration versus time curve from 0 hours extrapolated to infinity</paragraph>
                        <paragraph>[+]-α-HTBZ=[+]-α-dihydrotetrabenazine (active metabolite)</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
		     
	<content styleCode="italics">In Vivo Drug Interactions</content>
                        </paragraph>
                        <paragraph>
		     
	The effects of paroxetine, ketoconazole and rifampin on the exposure of valbenazine are summarized in <linkHtml href="#Figure2">Figure 2</linkHtml>.  </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 2:</content>
                           <content styleCode="bold">
		     
	Effects of Strong </content>
                           <content styleCode="bold">CYP2D6 and CYP3A4 Inhibitors and </content>
                           <content styleCode="bold">CYP3A4 Inducers on Valbenazine Pharmacokinetics</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure2" referencedObject="MM03000003"/>
                        </paragraph>
                        <paragraph>AUC<sub>inf</sub>=area under the plasma concentration versus time curve from 0 hours extrapolated to infinity</paragraph>
                        <paragraph>[+]-α-HTBZ=[+]-α-dihydrotetrabenazine (active metabolite)</paragraph>
                        <paragraph>
		     
	The effects of valbenazine on the exposure of other coadministered drugs are summarized in <linkHtml href="#Figure3">Figure 3</linkHtml>.  </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 3:</content>
                           <content styleCode="bold">
		     
	Effects of Valbenazine on Pharmacokinetics of Other Drugs</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure3" referencedObject="MM03000004"/>
                        </paragraph>
                        <paragraph>AUC<sub>inf</sub>=area under the plasma concentration versus time curve from 0 hours extrapolated to infinity</paragraph>
                        <paragraph>
		     
	<content styleCode="italics">In Vitro Drug Interactions</content>
                        </paragraph>
                        <paragraph>
		     
	The results of <content styleCode="italics">in vitro</content> studies suggest that valbenazine and [+]-α-HTBZ are unlikely to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 or CYP3A4/5, or induce CYP1A2, CYP2B6 or CYP3A4/5 at clinically relevant concentrations. </paragraph>
                        <paragraph>
		     
	The results of <content styleCode="italics">in vitro</content> studies suggest that valbenazine and [+]-α-HTBZ are unlikely to inhibit the transporters (BCRP, OAT1, OAT3, OCT2, OATP1B1, or OATP1B3) at clinically relevant concentrations.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_12_5_Pharmacogenomics">
                     <id root="bf2488d3-cf80-416c-ae3c-1fa9d6622de9"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="66106-6" displayName="PHARMACOGENOMICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.</content>
                        <content styleCode="bold">5</content>
                        <content styleCode="bold"> </content>
                        <content styleCode="bold">Pharmacogenomics</content>
                     </title>
                     <text>
                        <paragraph>CYP2D6 metabolizes the active metabolite of valbenazine ([+]-α-HTBZ). The gene encoding CYP2D6 has polymorphisms that impact protein function. CYP2D6 poor metabolizers are individuals with two non-functioning alleles, resulting in no enzyme activity. </paragraph>
                        <paragraph>Pharmacokinetic data from CYP2D6 poor metabolizers (n=25) treated with valbenazine demonstrate an approximate 2-fold higher AUC<sub>inf</sub> and a 1.8-fold higher C<sub>max</sub> of [+]-α-HTBZ compared to normal metabolizers. Dosage reduction is recommended in CYP2D6 poor metabolizers <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_3_Dosage_Recommendations">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">), Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_5_4_QT_Prolongation">5.4</linkHtml>
                           </content>
                           <content styleCode="italics">), and Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_6_CYP2D6_Poor">8.6</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.  </paragraph>
                        <paragraph>In a clinical study, AUC of [+]-α-HTBZ was 22% higher and C<sub>max</sub> was 9% lower in intermediate metabolizers (n=7) as compared to normal metabolizers (n=11), which is not considered clinically relevant. The effects of ultrarapid metabolizer status on the pharmacokinetics of [+]-α-HTBZ have not been studied.  </paragraph>
                        <paragraph>Approximately 7% of White populations, 2% of Asian populations, and 2% of African-American populations are poor metabolizers.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="75af4183-d187-465b-88c6-888e780f5bc6"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13 </content>
                  <content styleCode="bold">NONCLINICAL TOXICOLOGY</content>
               </title>
               <effectiveTime value="20240430"/>
               <component>
                  <section>
                     <id root="0c1f4371-5d85-44c8-88a4-52f6742ea28b"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1 </content>
                        <content styleCode="bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Valbenazine did not increase tumors in rats treated orally for 91 weeks at 0.5, 1, and 2 mg/kg/day. These doses are &lt;1 times (0.06, 0.1, and 0.24 times, respectively) the MRHD of 80 mg/day based on mg/m<sup>2</sup>.</paragraph>
                        <paragraph>Valbenazine did not increase tumors in hemizygous Tg.rasH2 mice treated orally for 26 weeks at 10, 30 and 75 mg/kg/day, which are 0.6, 1.9 and 4.6 times the MRHD of 80 mg/day based on mg/m<sup>2</sup>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Valbenazine was not mutagenic in the <content styleCode="italics">in vitro</content> bacterial reverse mutation test (Ames) or clastogenic in the <content styleCode="italics">in vitro</content> mammalian chromosomal aberrations assay in human peripheral blood lymphocytes or in the <content styleCode="italics">in vivo</content> rat bone marrow micronucleus assay.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>In a fertility study, rats were treated orally with valbenazine at 1, 3, and 10 mg/kg/day prior to mating and through mating, for a minimum of 10 weeks (males) or through Day 7 of gestation (females). These doses are 0.1, 0.4, and 1.2 times the MRHD of 80 mg/day based on mg/m<sup>2</sup>, respectively. Valbenazine delayed mating in both sexes, which led to lower number of pregnancies and disrupted estrous cyclicity at the high dose, 1.2 times the MRHD of 80 mg/day based on mg/m<sup>2</sup>. Valbenazine had no effects on sperm parameters (motility, count, density) or on uterine parameters (corpora lutea, number of implants, viable implants, pre-implantation loss, early resorptions and post-implantation loss) at any dose. </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_14_CLINICAL_STUDIES">
               <id root="a6dcd573-93d2-4ed0-86b3-47c29035cc55"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14 </content>
                  <content styleCode="bold">CLINICAL STUDIES</content>
               </title>
               <effectiveTime value="20240430"/>
               <component>
                  <observationMedia ID="MM03000005">
                     <text>Figure 4</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000006">
                     <text>Figure 5</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000007">
                     <text>Figure6</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000008">
                     <text>Figure7</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <section ID="_14_1_Tardive_Dyskinesia">
                     <id root="352913e8-62b1-4ac0-9864-299adf2e935d"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.1</content>
                        <content styleCode="bold"> </content>
                        <content styleCode="bold">Tardive Dyskinesia</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">INGREZZA SPRINKLE</content>
                        </paragraph>
                        <paragraph>The effectiveness of INGREZZA SPRINKLE has been established from adequate and well-controlled studies of INGREZZA for the treatment of tardive dyskinesia. Presented below is a display of the efficacy results of the adequate and well-controlled studies of INGREZZA in patients with tardive dyskinesia.</paragraph>
                        <paragraph>
                           <content styleCode="underline">INGREZZA</content>
                        </paragraph>
                        <paragraph>A randomized, double-blind, placebo-controlled trial of INGREZZA was conducted in patients with moderate to severe tardive dyskinesia as determined by clinical observation. Patients had underlying schizophrenia, schizoaffective disorder, or a mood disorder. Individuals at significant risk for suicidal or violent behavior and individuals with unstable psychiatric symptoms were excluded. </paragraph>
                        <paragraph>The Abnormal Involuntary Movement Scale (AIMS) was the primary efficacy measure for the assessment of tardive dyskinesia severity. The AIMS is a 12-item scale; items 1 to 7 assess the severity of involuntary movements across body regions and these items were used in this study. Each of the 7 items was scored on a 0 to 4 scale, rated as: 0=no dyskinesia; 1=low amplitude, present during some but not most of the exam; 2=low amplitude and present during most of the exam (or moderate amplitude and present during some of the exam); 3=moderate amplitude and present during most of exam; or 4=maximal amplitude and present during most of exam. The AIMS dyskinesia total score (sum of items 1 to 7) could thus range from 0 to 28, with a decrease in score indicating improvement. The AIMS was scored by central raters who interpreted the videos blinded to subject identification, treatment assignment, and visit number.</paragraph>
                        <paragraph>The primary efficacy endpoint was the mean change from baseline in the AIMS dyskinesia total score at the end of Week 6. The change from baseline for two fixed doses of INGREZZA (40 mg or 80 mg) was compared to placebo. At the end of Week 6, subjects initially assigned to placebo were re-randomized to receive INGREZZA 40 mg or 80 mg. Subjects originally randomized to INGREZZA continued INGREZZA at their randomized dose. Follow-up was continued through Week 48 on the assigned drug, followed by a 4-week period off-drug (subjects were not blind to withdrawal).  </paragraph>
                        <paragraph>A total of 234 subjects were enrolled, with 29 (12%) discontinuing prior to completion of the placebo-controlled period. Mean age was 56 (range 26 to 84). Patients were 54% male and 46% female. Patients were 57% Caucasian, 38% African-American, and 5% other. Concurrent diagnoses included schizophrenia/schizoaffective disorder (66%) and mood disorder (34%). With respect to concurrent antipsychotic use, 70% of subjects were receiving atypical antipsychotics, 14% were receiving typical or combination antipsychotics, and 16% were not receiving antipsychotics. </paragraph>
                        <paragraph>Results are presented in <linkHtml href="#Table4">Table 4</linkHtml>, with the distribution of responses shown in <linkHtml href="#Figure4new">Figure 4</linkHtml>.  The change from baseline in the AIMS total dyskinesia score in the 80 mg INGREZZA group was statistically significantly different from the change in the placebo group. Subgroup analyses by gender, age, racial subgroup, underlying psychiatric diagnostic category, and concomitant antipsychotic medication did not suggest any clear evidence of differential responsiveness.</paragraph>
                        <paragraph>The mean changes in the AIMS dyskinesia total score by visit are shown in <linkHtml href="#Figure5new">Figure 5</linkHtml>. Among subjects remaining in the study at the end of the 48-week treatment (N=123 [52.6%]), following discontinuation of INGREZZA, the mean AIMS dyskinesia total score appeared to return toward baseline (there was no formal hypothesis testing for the change following discontinuation). </paragraph>
                        <table ID="Table4">
                           <caption>Table 4:
		     
	Primary Efficacy Endpoint – Severity of Tardive Dyskinesia at Baseline and the End of Week 6</caption>
                           <col width="126"/>
                           <col width="160"/>
                           <col width="138"/>
                           <col width="148"/>
                           <col width="148"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Treatment Group</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Mean Baseline Score (SD)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">LS Mean Change from Baseline (SEM)</content>
                                    <content styleCode="bold">
                                       <sup>**</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo-subtracted Difference (95% CI)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">AIMS Dyskinesia Total Score</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">INGREZZA 40 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9.8 (4.1)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.9 (0.4)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.8 (-3.0, -0.7)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">INGREZZA 80 mg*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10.4 (3.6)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-3.2 (0.4)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-3.1 (-4.2, -2.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">Placebo</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9.9 (4.3)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-0.1 (0.4)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>LS Mean=least-squares mean; SD=standard deviation; SEM=standard error of the mean; CI=2-sided 95% confidence interval<br/>*Dose that was statistically significantly different from placebo after adjusting for multiplicity.<br/>
                           <sup>**</sup>A negative change from baseline indicates improvement.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 4:</content>
                           <content styleCode="bold">
		     
	Percent of Patients with Specified Magnitude of AIMS Total Score Improvement at the End of Week 6</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure4new" referencedObject="MM03000005"/>
                        </paragraph>
                        <paragraph>ITT=Intent to Treat; This analysis set includes all randomized patients who had a baseline and at least one post-baseline AIMS dyskinesia total score value reported.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 5:</content>
                           <content styleCode="bold">
		     
	AIMS Dyskinesia Total Score Mean Change from Baseline – Entire Study Duration (Arithmetic Mean)</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure5new" referencedObject="MM03000006"/>
                        </paragraph>
                        <paragraph>DB=Double-Blind; After Week 6, subjects initially receiving placebo were re-randomized to receive INGREZZA 40 mg or 80 mg until the end of Week 48. Error bars represent ±1 Standard Error of the Mean (SEM).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Efficacy of INGREZZA 60 mg</content>
                        </paragraph>
                        <paragraph>Based on modeling and simulation, the predicted mean change from baseline in the AIMS dyskinesia total score at Week 6 for INGREZZA 60 mg once daily in subjects with TD is -2.69 (95% CI: -3.30, -2.13), which is within the efficacy range for INGREZZA 40 mg and 80 mg once daily.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="_14_2_Chorea_Associated">
                     <id root="c54711c1-4ca2-471e-a9a6-7130941863e2"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.2</content>
                        <content styleCode="bold"> </content>
                        <content styleCode="bold">Chorea Associated with Huntington</content>
                        <content styleCode="bold">’s</content>
                        <content styleCode="bold"> Disease</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">INGREZZA SPRINKLE</content>
                        </paragraph>
                        <paragraph>The effectiveness of INGREZZA SPRINKLE has been established from adequate and well-controlled studies of INGREZZA for the treatment of chorea associated with Huntington’s disease. Presented below is a display of the efficacy results of the adequate and well-controlled studies of INGREZZA in patients with chorea associated with Huntington’s disease.</paragraph>
                        <paragraph>
                           <content styleCode="underline">INGREZZA</content>
                        </paragraph>
                        <paragraph>A randomized, double-blind, placebo-controlled study was conducted to evaluate the efficacy, safety, and tolerability of INGREZZA in patients with chorea associated with Huntington’s disease (NCT04102579). Treatment duration was 12 weeks followed by a 2-week period off drug. INGREZZA was started at 40 mg per day and the dose could be increased every 2 weeks in 20 mg increments up to a maximum dosage of 80 mg per day. The primary efficacy endpoint was the change from baseline to the end of the treatment period (average of Week 10 and Week 12) in the Total Maximal Chorea score of the Unified Huntington’s Disease Rating Scale (UHDRS). The Total Maximal Chorea score is rated from 0 to 4 (with 0 representing no chorea) for 7 different parts of the body, with a total score ranging from 0 to 28.</paragraph>
                        <paragraph>A total of 128 patients were randomized into the study, and 125 patients were included in the analysis of efficacy. In these patients, the mean age was 54 years (range 25 to 74 years), 46% were male and 96% were White. Greater than 80% of patients were taking the 80 mg daily dosage at the end of the 12-week treatment period. </paragraph>
                        <paragraph>
                           <linkHtml href="#Table5">Table 5</linkHtml> and <linkHtml href="#Figure6">Figure 6</linkHtml> summarize the effects of INGREZZA on chorea based on the Total Maximal Chorea score. </paragraph>
                        <paragraph>The mean change in Total Maximal Chorea scores for patients receiving INGREZZA improved by 4.6 units (LS mean) from baseline to the end of the treatment period (average of Week 10 and Week 12), compared to 1.4 units in the placebo group. The treatment effect of -3.2 units was statistically significant (p&lt;0.0001) (<linkHtml href="#Figure6">Figure 6</linkHtml>). At the Week 14 follow-up visit (2 weeks after discontinuation of the study medication), the Total Maximal Chorea scores of patients who had received INGREZZA returned to baseline.</paragraph>
                        <table ID="Table5">
                           <caption>Table 5:
		     
	Primary Efficacy Endpoint - Mean Change from Baseline to End of Treatment in Total Maximal Chorea Score in Patients with Huntington’s Disease Treated with INGREZZA</caption>
                           <col width="114"/>
                           <col width="144"/>
                           <col width="144"/>
                           <col width="162"/>
                           <col width="150"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Primary Endpoint</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Treatment Group</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Mean Baseline Score (SD)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">LS Mean Change from Baseline (SEM)</content>
                                    <content styleCode="bold">
                                       <sup> b</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo-subtracted Difference </content>
                                    <content styleCode="bold">
                                       <br/>(95% CI)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">TMC Score</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">INGREZZA<br/>N=64</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12.2 (2.3)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-4.6 (0.4)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-3.2 (-4.4, -2.0)<br/>p &lt;0.0001</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">Placebo<br/>N=61</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12.1 (2.8)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.4 (0.4)</td>
                                 <td styleCode="Lrule Rrule " align="center"/>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a </sup>TMC, Total Maximal Chorea is a subscale of the Unified Huntington’s Disease Rating Scale (UHDRS) <br/>
                           <sup>b</sup> LS Mean=least-squares mean; SD=standard deviation; SEM=standard error of the mean; CI=2-sided 95% confidence interval</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 6:</content>
		     
	<content styleCode="bold">Mean Change in Total Maximal Chorea Score Over Time </content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure6" referencedObject="MM03000007"/>
                        </paragraph>
                        <paragraph>LSMD=least-squares mean difference (SEM) [INGREZZA – Placebo]</paragraph>
                        <paragraph>CI=confidence interval</paragraph>
                        <paragraph>SEM=standard error of the mean</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 7:</content>
                           <content styleCode="bold">
		     
	Distribution of the Change in Total Maximal Chorea Score (Average of Week 10 and 12)</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM03000008"/>
                        </paragraph>
                        <paragraph>Figure 7 shows the distribution of values for the change in Total Maximal Chorea Score. Negative values indicate a reduction in chorea and positive values indicate an increase in chorea.</paragraph>
                        <paragraph>In a clinician-rated global impression of change (CGI-C), clinicians rated 43% of patients treated with INGREZZA as “Much Improved” or “Very Much Improved” at the end of treatment, compared to 13% of patients who received placebo (p&lt;0.001).</paragraph>
                        <paragraph>A patient-rated global impression of change (PGI-C) assessed how patients rated their overall chorea symptoms. Of the patients treated with INGREZZA, 53% rated their symptoms as “Much Improved” or “Very Much Improved” at the end of treatment, compared to 26% of patients who received placebo (p &lt;0.01). </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="62071467-c734-4a54-8c09-c6760daea2f0"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16 </content>
                  <content styleCode="bold">HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">How Supplied</content>
                  </paragraph>
                  <paragraph>INGREZZA (valbenazine) capsules are available as:</paragraph>
                  <paragraph>
                     <content styleCode="bold">40 mg Capsule:  </content>White opaque body with a purple cap, printed with ‘VBZ’ and ‘40’ in black ink.</paragraph>
                  <paragraph>
                     <content styleCode="bold">60 mg Capsule:</content>  Dark red opaque body with a purple cap, printed with ‘VBZ’ and ‘60’ in black ink.</paragraph>
                  <paragraph>
                     <content styleCode="bold">80 mg Capsule:  </content>Purple opaque body and cap, printed with ‘VBZ’ and ‘80’ in black ink.</paragraph>
                  <paragraph>INGREZZA SPRINKLE (valbenazine) capsules are available as:</paragraph>
                  <paragraph>
                     <content styleCode="bold">40 mg Capsule:</content>  Pearl white opaque cap and body, printed with a band, directional arrows, and “VBZ 40” in black ink on both the cap and body.</paragraph>
                  <paragraph>
                     <content styleCode="bold">60 mg Capsule:</content>  Pearl white opaque cap and body, printed with a band, directional arrows, and “VBZ 60” in dark red ink on both the cap and body.</paragraph>
                  <paragraph>
                     <content styleCode="bold">80 mg Capsule:</content>  Pearl white opaque cap and body, printed with a band, directional arrows, and “VBZ 80” in purple ink on both the cap and body.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 6:</content>
                     <content styleCode="bold">
		     
	INGREZZA and INGREZZA SPRINKLE Configurations and NDC Numbers</content>
                  </paragraph>
                  <table>
                     <col width="173"/>
                     <col width="242"/>
                     <col width="208"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <content styleCode="bold">Package Configuration</content>
                           </td>
                           <td styleCode="Toprule Rrule " align="center">
                              <content styleCode="bold">Capsule Strength</content>
                           </td>
                           <td styleCode="Toprule Rrule ">
                              <content styleCode="bold">NDC Number</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">INGREZZA</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">Bottle of 30</td>
                           <td styleCode="Toprule Rrule " align="center">40 mg</td>
                           <td styleCode="Toprule Rrule ">NDC 70370-2040-1</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">Bottle of 30</td>
                           <td styleCode="Toprule Rrule " align="center">60 mg</td>
                           <td styleCode="Toprule Rrule ">NDC 70370-1060-1</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">Bottle of 30</td>
                           <td styleCode="Toprule Rrule " align="center">80 mg</td>
                           <td styleCode="Toprule Rrule ">NDC 70370-1080-1</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">4-week Initiation Pack<br/>for tardive dyskinesia</td>
                           <td styleCode="Toprule Rrule " align="center">28-day blister pack containing: <br/>7 x 40 mg and 21 x 80 mg</td>
                           <td styleCode="Toprule Rrule ">NDC 70370-2048-6</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">4-week Initiation Pack<br/>for chorea associated with Huntington’s disease</td>
                           <td styleCode="Toprule Rrule " align="center">28-day blister pack containing:<br/>14 x 40 mg and 14 x 60 mg</td>
                           <td styleCode="Toprule Rrule ">NDC 70370-2046-1</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">INGREZZA SPRINKLE</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">Bottle of 30</td>
                           <td styleCode="Toprule Rrule " align="center">40 mg</td>
                           <td styleCode="Toprule Rrule ">NDC 70370-4040-1</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">Bottle of 30</td>
                           <td styleCode="Toprule Rrule " align="center">60 mg</td>
                           <td styleCode="Toprule Rrule ">NDC 70370-4060-1</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">Bottle of 30</td>
                           <td styleCode="Toprule Rrule " align="center">80 mg</td>
                           <td styleCode="Toprule Rrule ">NDC 70370-4080-1</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Storage</content>
                  </paragraph>
                  <paragraph>INGREZZA: Store at 15°C to 30°C (59°F to 86°F).</paragraph>
                  <paragraph>INGREZZA SPRINKLE: Store at 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from moisture. Dispense in original container or in a tight container as defined in USP.</paragraph>
               </text>
               <effectiveTime value="20240430"/>
            </section>
         </component>
         <component>
            <section>
               <id root="d1d2d668-9a17-4bea-a834-a7d4fe41adb7"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17 </content>
                  <content styleCode="bold">PATIENT COUNSELING INFORMATION</content>
               </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#MedGuide">Medication Guide</linkHtml> and <linkHtml href="#IFU">Instructions for Use</linkHtml>).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Depression and Suicidal Ideation and Behavior in Patients with Huntington’s Disease</content>
                  </paragraph>
                  <paragraph>Inform patients, their caregivers, and families of the risks of depression, worsening depression, and suicidal ideation and behavior associated with INGREZZA and INGREZZA SPRINKLE, and instruct them to report behaviors of concern promptly to the treating physician. Patients with Huntington’s disease who express suicidal ideation should be evaluated immediately <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_1_Depression_and">5.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity Reactions</content>
                  </paragraph>
                  <paragraph>Inform patients about the signs and symptoms of hypersensitivity reactions, such as angioedema, including difficulty breathing, swelling of the face, lips, eyelids, tongue or throat. Advise patients to discontinue INGREZZA or INGREZZA SPRINKLE immediately if any of these reactions occur and report to the emergency room if symptoms of angioedema occur <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_2_Hypersensitivity_Reactions">5.2</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Somnolence</content>
                     <content styleCode="underline"> and Sedation</content>
                  </paragraph>
                  <paragraph>Inform patients that INGREZZA and INGREZZA SPRINKLE may cause somnolence and may impair the ability to perform tasks that require complex motor and mental skills. Advise patients that until they learn how they respond to INGREZZA or INGREZZA SPRINKLE, they should be careful or avoid doing activities that require them to be alert, such as driving a car or operating machinery <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_3_Somnolence_and">5.3</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Prolongation of the QT Interval</content>
                  </paragraph>
                  <paragraph>Inform patients to consult their physician immediately if they feel faint, lose consciousness, or have heart palpitations <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_4_QT_Prolongation">5.4</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>. Advise patients to inform physicians that they are taking INGREZZA or INGREZZA SPRINKLE before any new drug is taken.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Neuroleptic Malignant Syndrome (NMS)</content>
                  </paragraph>
                  <paragraph>Counsel patients about a potentially fatal adverse reaction – neuroleptic malignant syndrome (NMS) – that has been reported in association with administration of VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE. Advise patients to contact a healthcare provider or report to the emergency room if they experience signs or symptoms of NMS <content styleCode="italics">[</content>
                     <content styleCode="italics">see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_5_Neuroleptic_Malignant">5.5</linkHtml>
                     </content>
                     <content styleCode="italics">)</content>
                     <content styleCode="italics">]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Parkinsonism</content>
                  </paragraph>
                  <paragraph>Inform patients that parkinson-like symptoms may occur while taking INGREZZA or INGREZZA SPRINKLE.  Advise patients to consult their healthcare provider if they experience difficulty moving or loss of ability to move muscles voluntarily, tremor, gait disturbances, or drooling <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_6_Parkinsonism">5.6</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy</content>
                  </paragraph>
                  <paragraph>Advise a pregnant patient of the potential risk to a fetus <content styleCode="italics">[see </content>
                     <content styleCode="italics">Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_8_1_Pregnancy">8.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation </content>
                  </paragraph>
                  <paragraph>Advise a woman not to breastfeed during treatment with INGREZZA or INGREZZA SPRINKLE and for 5 days after the final dose<content styleCode="italics"> </content>
                     <content styleCode="italics">[see Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_8_2_Lactation">8.2</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>Administration Information for INGREZZA SPRINKLE</paragraph>
                  <paragraph>Advise patients to read and follow the Instructions for Use for INGREZZA SPRINKLE.</paragraph>
                  <paragraph>Advise the patient of the following:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>INGREZZA SPRINKLE may be opened and the entire contents of the capsule sprinkled over a bowl containing a small amount (1 tablespoonful) of soft food such as applesauce, yogurt, or pudding. Stir the contents of the capsule into the soft food.<br/>○ Do not sprinkle the contents of the capsule into milk or drinking water.<br/>○ Swallow the drug/food mixture immediately.<br/>○ The mixture may be stored for up to 2 hours at room temperature. Discard any unused portion after 2 hours.<br/>○ Drink a glass (e.g., 240 mL) of water following administration of the drug/food mixture <content styleCode="italics">[see Dosage and Administration (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_2_2_Administrative_Information">2.2</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>.<br/>
                     </item>
                     <item>INGREZZA SPRINKLE may also be swallowed whole with water <content styleCode="italics">[see Dosage and Administration (2.2)]</content>. Do not crush or chew INGREZZA SPRINKLE.</item>
                  </list>
                  <paragraph>For further information on INGREZZA or INGREZZA SPRINKLE, call 84-INGREZZA (844-647-3992).</paragraph>
                  <paragraph>Distributed by: </paragraph>
                  <paragraph>Neurocrine Biosciences, Inc.<br/>12780 El Camino Real <br/>San Diego, CA 92130</paragraph>
                  <paragraph>INGREZZA is a registered trademark of Neurocrine Biosciences, Inc.</paragraph>
                  <paragraph>098854011</paragraph>
               </text>
               <effectiveTime value="20240430"/>
            </section>
         </component>
         <component>
            <section>
               <id root="010a4dff-1b29-446e-bd84-ac1d54787c64"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42231-1" displayName="SPL MEDGUIDE SECTION"/>
               <title/>
               <text>
                  <table ID="MedGuide">
                     <col width="288"/>
                     <col width="81"/>
                     <col width="369"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3" align="center">
                              <content styleCode="bold">MEDICATION GUIDE</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="2" align="center">
                              <content styleCode="bold">INGREZZA® (in greh' zah)</content>
                              <br/>
                              <content styleCode="bold">(valbenazine)</content>
                              <br/>
                              <content styleCode="bold">capsules</content>
                           </td>
                           <td styleCode="Rrule " align="center">
                              <content styleCode="bold">INGREZZA® SPRINKLE (in greh' zah spring kuhl)</content>
                              <br/>
                              <content styleCode="bold">(valbenazine)</content>
                              <br/>
                              <content styleCode="bold">capsules</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">What is the most important information I should know about INGREZZA</content>
                              <content styleCode="bold"> or INGREZZA SPRINKLE</content>
                              <content styleCode="bold">?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>INGREZZA or INGREZZA SPRINKLE can cause serious side effects in people with Huntington’s disease, including:<br/>◦ depression<br/>◦ suicidal thoughts<br/>◦ suicidal actions <br/>
                                 </item>
                                 <item>Tell your healthcare provider before you start taking INGREZZA or INGREZZA SPRINKLE if you have Huntington’s disease and are depressed (have untreated depression or depression that is not well controlled by medicine) <content styleCode="bold">or</content> have suicidal thoughts. <br/>
                                 </item>
                                 <item>Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is especially important when INGREZZA or INGREZZA SPRINKLE is started and when the dose is changed.</item>
                              </list>
                              <content styleCode="bold">Call </content>
                              <content styleCode="bold">your </content>
                              <content styleCode="bold">healthcare provider right away if you become depressed or have any of the following symptoms, especially if they are new, worse, or worry you:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>feel sad or have crying spells <br/>
                                 </item>
                                 <item>lose interest in seeing your friends or doing things you used to enjoy <br/>
                                 </item>
                                 <item>sleep a lot more or a lot less than usual <br/>
                                 </item>
                                 <item>feel unimportant <br/>
                                 </item>
                                 <item>feel guilty <br/>
                                 </item>
                                 <item>feel hopeless or helpless <br/>
                                 </item>
                                 <item>feel more irritable, angry or aggressive than usual <br/>
                                 </item>
                                 <item>feel more or less hungry than usual or notice a big change in your body weight <br/>
                                 </item>
                                 <item>have trouble paying attention <br/>
                                 </item>
                                 <item>feel tired or sleepy all the time <br/>
                                 </item>
                                 <item>have thoughts about hurting yourself or ending your life</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">What is INGREZZA</content>
                              <content styleCode="bold"> or INGREZZA SPRINKLE</content>
                              <content styleCode="bold">? </content>
                              <br/>INGREZZA or INGREZZA SPRINKLE is a prescription medicine used to treat adults with:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).<br/>
                                 </item>
                                 <item>the involuntary movements (chorea) of Huntington’s disease. INGREZZA or INGREZZA SPRINKLE does not cure the cause of the involuntary movements, and it does not treat other symptoms of Huntington’s disease, such as problems with thinking or emotions.</item>
                              </list>It is not known if INGREZZA or INGREZZA SPRINKLE is safe and effective in children.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Who should not take INGREZZA or INGREZZA SPRINKLE?</content>
                              <br/>
                              <content styleCode="bold">Do not take INGREZZA </content>
                              <content styleCode="bold">or </content>
                              <content styleCode="bold">INGREZZA SPRINKLE </content>
                              <content styleCode="bold">if you</content> are allergic to valbenazine, or any of the ingredients in INGREZZA or INGREZZA SPRINKLE. See the end of this Medication Guide for a complete list of ingredients in INGREZZA or INGREZZA SPRINKLE.<content styleCode="bold"> </content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Before taking INGREZZA</content>
                              <content styleCode="bold"> or INGREZZA SPRINKLE</content>
                              <content styleCode="bold">, tell your healthcare provider about all of your medical conditions</content>
                              <content styleCode="bold">,</content>
                              <content styleCode="bold"> including if you: </content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have emotional or mental problems (for example, depression, nervousness, anxiety, anger, agitation, psychosis, previous suicidal thoughts or suicide attempts)<br/>
                                 </item>
                                 <item>have liver problems <br/>
                                 </item>
                                 <item>have heart disease that is not stable, have heart failure or recently had a heart attack <br/>
                                 </item>
                                 <item>have an irregular heart rhythm or heartbeat (QT prolongation, heart arrhythmia) <br/>
                                 </item>
                                 <item>are pregnant or plan to become pregnant. INGREZZA or INGREZZA SPRINKLE may harm your unborn baby. <br/>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if INGREZZA or INGREZZA SPRINKLE passes into your breast milk. <content styleCode="bold">Do not</content> breastfeed during treatment with INGREZZA or INGREZZA SPRINKLE and for 5 days after the final dose. Talk to your healthcare provider about the best way to feed your baby during treatment with INGREZZA or INGREZZA SPRINKLE.   </item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins and herbal supplements. Make sure you tell <content styleCode="bold">all of</content> your healthcare providers that you are taking INGREZZA or INGREZZA SPRINKLE. Taking INGREZZA or INGREZZA SPRINKLE with certain other medicines may cause serious side effects and may affect the way that INGREZZA or INGREZZA SPRINKLE works. <content styleCode="bold">Especially tell your healthcare provider if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>take or have taken a monoamine oxidase inhibitor (MAOI) medicine. You should not take INGREZZA or INGREZZA SPRINKLE if you are taking, or have stopped taking, a MAOI within the last 14 days. Ask your healthcare provider if you are not sure if you take a MAOI.<br/>
                                 </item>
                                 <item>take digoxin</item>
                              </list>
                              <content styleCode="bold">Do not start any new medicines </content>
                              <content styleCode="bold">during treatment with</content>
                              <content styleCode="bold"> INGREZZA </content>
                              <content styleCode="bold">or INGREZZA SPRINKLE </content>
                              <content styleCode="bold">without talking to your healthcare provider first.</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">How should I take INGREZZA</content>
                              <content styleCode="bold"> or INGREZZA SPRINKLE</content>
                              <content styleCode="bold">?</content> <list listType="unordered" styleCode="Disc">
                                 <item>Take INGREZZA or INGREZZA SPRINKLE exactly as your healthcare provider tells you to. <br/>
                                 </item>
                                 <item>Your healthcare provider may change your dose of INGREZZA or INGREZZA SPRINKLE during treatment. <br/>
                                 </item>
                                 <item>Take INGREZZA or INGREZZA SPRINKLE 1 time each day.<br/>
                                 </item>
                                 <item>Take INGREZZA or INGREZZA SPRINKLE with or without food.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">If you take INGREZZA,</content> swallow the capsule<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">If you take INGREZZA SPRINKLE:</content>
                                    <br/>○ You may open the capsule and sprinkle the contents (granules) over a small amount (1 tablespoonful) of soft food such as applesauce, yogurt, or pudding before taking INGREZZA SPRINKLE.<br/>○ You may also swallow the capsule whole with water.<br/>○ <content styleCode="bold">Do not</content> add the granules to milk or water. <br/>○ <content styleCode="bold">Do not</content> crush or chew INGREZZA SPRINKLE.<br/>○ <content styleCode="bold">See the detailed Instructions for Use on how to take a dose of INGREZZA SPRINKLE.</content>
                                    <br/>
                                 </item>
                                 <item>If you take too much INGREZZA or INGREZZA SPRINKLE, call your healthcare provider or Poison Help line at 1-800-222-1222, or go to the nearest hospital emergency room right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">What should I avoid while taking INGREZZA</content>
                              <content styleCode="bold"> or INGREZZA SPRINKLE</content>
                              <content styleCode="bold">?</content>
                              <br/>
                              <content styleCode="bold">Do not</content> drive a car or operate dangerous machinery until you know how INGREZZA or INGREZZA SPRINKLE affects you because INGREZZA or INGREZZA SPRINKLE can cause sleepiness and tiredness that could cause slow reaction times. Drinking alcohol and taking other medicines that may also cause sleepiness during treatment with INGREZZA or INGREZZA SPRINKLE may increase any sleepiness caused by INGREZZA or INGREZZA SPRINKLE.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">What are the possible side effects of INGREZZA</content>
                              <content styleCode="bold"> or INGREZZA SPRINKLE</content>
                              <content styleCode="bold">?</content>
                              <br/>
                              <content styleCode="bold">INGREZZA </content>
                              <content styleCode="bold">or INGREZZA SPRINKLE </content>
                              <content styleCode="bold">can</content>
                              <content styleCode="bold"> </content>
                              <content styleCode="bold">cause serious side effects, including: </content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>See <content styleCode="bold">“What is the most important information I should know about INGREZZA or INGREZZA SPRINKLE?”</content>
                                    <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Allergic Reactions.</content> Allergic reactions, including an allergic reaction that causes sudden swelling called angioedema, can happen <content styleCode="bold">after taking the first dose or after many doses of INGREZZA or INGREZZA SPRINKLE.</content> Signs and symptoms of allergic reactions and angioedema include:<br/>○ trouble breathing or shortness of breath<br/>○ swelling of your face, lips, eyelids, tongue, or throat, or other areas of your skin<br/>○ trouble with swallowing<br/>○ rash, including raised, itchy red areas on your skin (hives)<br/>
                                    <content styleCode="bold">Swelling in the throat can be life-threatening and can lead to death.</content> Stop taking INGREZZA or INGREZZA SPRINKLE right away and go to the nearest emergency room right away if you develop these signs and symptoms of allergic reactions and angioedema.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Sleepiness and tiredness that could cause slow reaction times (somnolence and sedation).</content> See <content styleCode="bold">“What should I avoid while taking INGREZZA or INGREZZA SPRINKLE?”</content>
                                    <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Heart rhythm problems (QT prolongation).</content> INGREZZA or INGREZZA SPRINKLE may cause a heart rhythm problem known as QT prolongation. You have a higher chance of getting QT prolongation if you also take certain other medicines during treatment with INGREZZA or INGREZZA SPRINKLE. Tell your healthcare provider right away if you develop any signs or symptoms of QT prolongation, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="2">     ◦ fast, slow, or irregular heartbeat (heart palpitations)</td>
                           <td styleCode="Rrule ">◦ shortness of breath</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="2">     ◦ dizziness or lightheadedness</td>
                           <td styleCode="Rrule ">◦ fainting or feeling like you are going to faint.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="3">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Neuroleptic Malignant Syndrome (NMS).</content> NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these signs and symptoms that do not have another obvious cause:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">     ◦ high fever</td>
                           <td styleCode="Rrule " colspan="2">◦ stiff muscles</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">     ◦ problems thinking</td>
                           <td styleCode="Rrule " colspan="2">◦ irregular pulse or blood pressure</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">     ◦ increased sweating</td>
                           <td styleCode="Rrule " colspan="2">◦ very fast or uneven heartbeat</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="3">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Parkinson-like symptoms.</content> Tell your healthcare provider if you develop any Parkinson-like symptoms during treatment with INGREZZA or INGREZZA SPRINKLE, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="2">     ◦ body stiffness</td>
                           <td styleCode="Rrule ">◦ drooling</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="2">     ◦ trouble moving or walking</td>
                           <td styleCode="Rrule ">◦ trouble keeping your balance</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="2">     ◦ shaking (tremors)</td>
                           <td styleCode="Rrule ">◦ falls</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="3">
                              <content styleCode="bold">The most c</content>
                              <content styleCode="bold">ommon side effect </content>
                              <content styleCode="bold">of</content>
                              <content styleCode="bold"> INGREZZA </content>
                              <content styleCode="bold">or INGREZZA SPRINKLE in people with tardive dyskinesia </content>
                              <content styleCode="bold">i</content>
                              <content styleCode="bold">s s</content>
                              <content styleCode="bold">leepiness </content>
                              <content styleCode="bold">and tiredness that could cause slow reaction times.</content>
                              <br/>
                              <content styleCode="bold">The most c</content>
                              <content styleCode="bold">ommon side effect</content>
                              <content styleCode="bold">s</content>
                              <content styleCode="bold"> </content>
                              <content styleCode="bold">of</content>
                              <content styleCode="bold"> INGREZZA </content>
                              <content styleCode="bold">or INGREZZA SPRINKLE in people with chorea associated with Huntington’s disease include </content>
                              <content styleCode="bold">sleepiness</content>
                              <content styleCode="bold"> </content>
                              <content styleCode="bold">and tiredness that could cause slow reaction times, raised itchy red areas on your skin (hives), rash, and trouble getting to sleep or staying asleep.</content>
                              <br/>Your doctor may change your dose, temporarily stop, or permanently stop treatment with INGREZZA or INGREZZA SPRINKLE if you develop certain side effects.<br/>These are not all of the possible side effects of INGREZZA or INGREZZA SPRINKLE. <br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">How should I store INGREZZA</content>
                              <content styleCode="bold"> or INGREZZA SPRINKLE</content>
                              <content styleCode="bold">?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store INGREZZA at 59°F to 86°F (15°C to 30°C). <br/>
                                 </item>
                                 <item>Store INGREZZA SPRINKLE between 68°F to 77°F (20°C to 25°C).<br/>
                                 </item>
                                 <item>Keep the bottle tightly closed to protect INGREZZA SPRINKLE from moisture.<br/>
                                 </item>
                                 <item>INGREZZA SPRINKLE granules added to soft food can be stored for up to 2 hours at room temperature between 68°F to 77°F (20°C to 25°C). After 2 hours, throw away any unused portion.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Keep INGREZZA</content>
                                    <content styleCode="bold">, INGREZZA SPRINKLE</content>
                                    <content styleCode="bold"> and all medicines out of the reach of children. </content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">General information about the safe and effective use of INGREZZA</content>
                              <content styleCode="bold"> or INGREZZA SPRINKLE.</content>
                              <content styleCode="bold"> </content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in  the Medication Guide. Do not use INGREZZA or INGREZZA SPRINKLE for a condition for which it was not prescribed.  Do not give INGREZZA or INGREZZA SPRINKLE to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about INGREZZA or INGREZZA SPRINKLE that is written for healthcare professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">What are the ingredients in INGREZZA</content>
                              <content styleCode="bold"> or INGREZZA SPRINKLE</content>
                              <content styleCode="bold">? </content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content>  valbenazine<br/>
                              <content styleCode="bold">INGREZZA </content>
                              <content styleCode="bold">Inactive ingredients:</content> hypromellose, isomalt, magnesium stearate, pregelatinized starch, and silicified microcrystalline cellulose.  The capsule shells contain candurin silver fine, FD&amp;C Blue#1, FD&amp;C Red#40, and gelatin.<br/>
                              <content styleCode="bold">INGREZZA SPRINKLE i</content>
                              <content styleCode="bold">nactive ingredients:</content> silicified microcrystalline cellulose, isomalt, pregelatinized maize starch, hypromellose, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc. The hard gelatin capsule shells contain gelatin and candurin silver fine.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">Distributed by: Neurocrine Biosciences, Inc., San Diego, CA 92130, U.S.A.<br/>For more information, go to www.INGREZZA.com or call 84-INGREZZA (844-647-3992).</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration
		     
	
		     
	
		     
	
		     
	
		     
	Revised: 4/2024</paragraph>
               </text>
               <effectiveTime value="20240430"/>
            </section>
         </component>
         <component>
            <section>
               <id root="a75db8e5-abf9-4dd6-b3ff-67f9edaf5f13"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="59845-8" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title/>
               <text>
                  <table ID="IFU">
                     <col width="343"/>
                     <col width="136"/>
                     <col width="251"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3" align="center">
                              <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                              <content styleCode="bold"/>
                              <br/>
                              <content styleCode="bold">INGREZZA</content>
                              <content styleCode="bold">
                                 <sup>®</sup>
                              </content>
                              <content styleCode="bold"> </content>
                              <content styleCode="bold">SPRINKLE </content>
                              <content styleCode="bold">(in greh</content>
                              <content styleCode="bold">'</content>
                              <content styleCode="bold"> zah</content>
                              <content styleCode="bold"> spring kuhl)</content>
                              <content styleCode="bold"> </content>
                              <br/>
                              <content styleCode="bold">(valbenazine) </content>
                              <br/>
                              <content styleCode="bold">capsules</content>
                              <content styleCode="bold"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">This Instructions for Use contains information on how to take INGREZZA SPRINKLE.<br/>
                              <content styleCode="bold">Important Information You Need to Know Before Taking INGREZZA SPRINKLE</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>You can open the INGREZZA SPRINKLE capsule and sprinkle the contents (granules) on soft food such as applesauce, yogurt, or pudding before you take it.<br/>
                                 </item>
                                 <item>You can also swallow the INGREZZA SPRINKLE capsule whole with water with or without food.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> add the granules to milk or water before you take INGREZZA SPRINKLE.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>take<content styleCode="bold"> </content>INGREZZA SPRINKLE through a nasogastric tube (NG Tube), gastrostomy tube (G Tube), or other feeding tube because it may clog the tube.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> crush or chew INGREZZA SPRINKLE.<br/>
                                 </item>
                                 <item>Check to make sure that you have received your prescribed strength of INGREZZA SPRINKLE before taking your dose.<br/>
                                 </item>
                                 <item>Check the expiration date on the INGREZZA SPRINKLE bottle.<content styleCode="bold"> Do not</content> take INGREZZA SPRINKLE if it is expired. Call your healthcare provider or pharmacist if your medicine is expired.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule ">
                              <content styleCode="bold">P</content>
                              <content styleCode="bold">repar</content>
                              <content styleCode="bold">ing to Take</content>
                              <content styleCode="bold"> INGREZZA S</content>
                              <content styleCode="bold">PRINKLE </content>
                              <br/>
                              <content styleCode="bold">Step 1</content>
                              <br/>
                              <content styleCode="bold">Gather your supplies.</content>
                              <content styleCode="bold"> </content>
                              <br/>You will need (see Figure A):<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>The prescribed number of INGREZZA SPRINKLE capsules.<br/>
                                 </item>
                                 <item>Soft food such as applesauce, yogurt, or pudding. You will need 1 tablespoonful of soft food.<br/>
                                 </item>
                                 <item>A clean tablespoon. <br/>
                                 </item>
                                 <item>A clean container such as a small cup or bowl.</item>
                              </list>
                           </td>
                           <td styleCode="Toprule Rrule " colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM03000009"/>
                              <br/>Figure A.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule ">
                              <content styleCode="bold">Step 2</content>
                              <br/>Wash and dry your hands (see Figure B).<br/>
                           </td>
                           <td styleCode="Toprule Rrule " colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM0300000A"/>
                              <br/>Figure B.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Step 3</content>
                              <br/>Place the following items on a clean flat surface:<list listType="unordered" styleCode="Disc">
                                 <item>A tablespoon.<br/>
                                 </item>
                                 <item>A container of soft food such as applesauce, yogurt, or pudding.</item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>The number of capsules you will need for your prescribed dose.<br/>
                                 </item>
                                 <item>A small cup or bowl.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule ">
                              <content styleCode="bold">Step 4</content>
                              <br/>Place 1 tablespoonful of soft food into a small cup or bowl (see Figure C).</td>
                           <td styleCode="Toprule Rrule " colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM0300000B"/>
                              <br/>Figure C.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule ">
                              <content styleCode="bold">Step 5</content>
                              <br/>
                              <content styleCode="bold">Open</content>
                              <content styleCode="bold">ing</content>
                              <content styleCode="bold"> the INGREZZA SPRINKLE capsule</content>
                              <content styleCode="bold"> and sprinkl</content>
                              <content styleCode="bold">ing the granules </content>
                              <content styleCode="bold">on the </content>
                              <content styleCode="bold">soft </content>
                              <content styleCode="bold">food</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Hold the INGREZZA SPRINKLE capsule carefully over the soft food (see Figure D).<br/>
                                 </item>
                                 <item>Gently pull the INGREZZA SPRINKLE capsule apart, empty the capsule contents (granules) onto the soft food (see Figure E). </item>
                              </list>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                           </td>
                           <td styleCode="Toprule Rrule " colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM0300000C"/>
                              <br/>Figure D.<br/>
                              <renderMultiMedia referencedObject="MM0300000D"/>
                              <br/>Figure E.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule ">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Check the capsule to make sure that you did not miss any granules.<br/>
                                 </item>
                                 <item>Tap the capsule to remove any remaining granules. <br/>
                                 </item>
                                 <item>Stir the granules into the soft food with the tablespoon (see Figure F).</item>
                              </list>
                              <content styleCode="bold">Do not</content> crush the granules while stirring them into the soft food.<br/>
                           </td>
                           <td styleCode="Toprule Rrule " colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM0300000E"/>
                              <br/>Figure F.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Step 6</content>
                              <br/>
                              <content styleCode="bold">Tak</content>
                              <content styleCode="bold">ing</content>
                              <content styleCode="bold"> the soft food and INGREZZA S</content>
                              <content styleCode="bold">PRINKLE</content>
                              <content styleCode="bold"> mixture</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Eat all of the food <content styleCode="bold">right away</content> after adding the granules. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do no</content>
                                    <content styleCode="bold">t </content>chew the granules.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">After eating all of the INGREZZA SPRINKLE soft food mixture, </content>drink a glass of water (about 8 ounces or 240 mL) to make sure that all of the medicine is swallowed.<br/>
                                 </item>
                                 <item>If you need to, you can store the mixture for up to 2 hours at room temperature between 68°F to 77°F (20°C to 25°C). After 2 hours, throw away any unused portion of the mixture.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule ">
                              <content styleCode="bold">Step 7</content>
                              <br/>
                              <content styleCode="bold">Cleaning Up and Disposing of INGREZZA SPRINKLE</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Throw away (dispose of) the empty capsule shells in your household trash (see Figure G).<br/>
                                 </item>
                                 <item>Wash your hands and all the items used to prepare and take INGREZZA SPRINKLE.</item>
                              </list>Ask your pharmacist how to dispose of expired medicines or medicines you no longer use.</td>
                           <td styleCode="Toprule Rrule " colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM0300000F"/>
                              <br/>Figure G.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Storing INGREZZA SPRINKLE</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store INGREZZA SPRINKLE between 68°F to 77°F (20°C to 25°C).<br/>
                                 </item>
                                 <item>Protect INGREZZA SPRINKLE from moisture to help keep the capsules dry.<br/>
                                 </item>
                                 <item>INGREZZA SPRINKLE granules added to soft food can be stored for up 2 hours at room temperature between 68°F to 77°F (20°C to 25°C). After 2 hours, throw away any unused portion. </item>
                              </list>
                              <content styleCode="bold">Keep INGREZZA SPRINKLE and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">Distributed by: Neurocrine Biosciences, Inc., San Diego, CA 92130<br/>For more information, go to www.INGREZZA.com or call 84-INGREZZA (844-647-3992).</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule " colspan="2">This Instructions for Use has been approved by the U.S. Food and Drug Administration. </td>
                           <td styleCode="Toprule " align="right">Approved: 4/2024</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <observationMedia ID="MM03000009">
                     <text>Figure A </text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000A">
                     <text>Figure B</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-0a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000B">
                     <text>Figure C</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-0b.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000C">
                     <text>Figure D</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-0c.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000D">
                     <text>Figure E</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-0d.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000E">
                     <text>Figure F</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-0e.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000F">
                     <text>Figure G</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-0f.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="6a277970-afdd-48d8-a095-d5a94d364338"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>NDC 70370-2040-1<br/>INGREZZA<br/>(valbenazine) capsules<br/>40 mg<br/>30 Capsules<br/>Rx Only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000010"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <observationMedia ID="MM03000010">
                     <text>NDC 70370-2040-1
INGREZZA
(valbenazine) capsules
40 mg
30 Capsules
Rx Only
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="ed1c2a65-7a51-40b5-aace-58768032960e"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>NDC 70370-1060-1<br/>INGREZZA<br/>(valbenazine) capsules<br/>60 mg<br/>30 Capsules<br/>Rx Only</paragraph>
                  <paragraph> <renderMultiMedia referencedObject="MM03000011"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <observationMedia ID="MM03000011">
                     <text>NDC 70370-1060-1
INGREZZA
(valbenazine) capsules
60 mg
30 Capsules
Rx Only
 </text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="3c5c7b26-8021-4d1d-8f36-5a86aa965627"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>NDC 70370-1080-1<br/>INGREZZA<br/>(valbenazine) capsules<br/>80 mg<br/>30 Capsules<br/>Rx Only</paragraph>
                  <paragraph> <renderMultiMedia referencedObject="MM03000012"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <observationMedia ID="MM03000012">
                     <text>NDC 70370-1080-1
INGREZZA
(valbenazine) capsules
80 mg
30 Capsules
Rx Only
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="9bc4d257-da20-423a-8173-a3d381e0f3c7"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>NDC 70370-2048-6<br/>INGREZZA<br/>(valbenazine) capsules<br/>7 x 40 mg / 21 x 80 mg capsules<br/>28-day Initiation Pack<br/>Rx Only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000013"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <observationMedia ID="MM02000013">
                     <text>PRINCIPAL DISPLAY PANEL
NDC 70370-2048-6
INGREZZA
(valbenazine) capsules
7 x 40 mg / 21 x 80 mg capsules
28-day Initiation Pack
Rx Only
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="18cc5dcb-30e9-4963-9135-3115404e270b"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>NDC 70370-2046-1<br/>INGREZZA<br/>(valbenazine) capsules<br/>14 x 40 mg / 14 x 60 mg capsules<br/>28-day Initiation Pack<br/>Rx Only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000014"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <observationMedia ID="MM02000014">
                     <text>PRINCIPAL DISPLAY PANEL
NDC 70370-2046-1
INGREZZA
(valbenazine) capsules
14 x 40 mg / 14 x 60 mg capsules
28-day Initiation Pack
Rx Only
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b488d27c-cf91-4727-a3b1-155193a03865"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>NDC 70370-4040-1<br/>INGREZZA SPRINKLE<br/>(valbenazine) capsules<br/>40 mg<br/>30 capsules<br/>Rx Only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000015"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <observationMedia ID="MM03000015">
                     <text>NDC 70370-4040-1
INGREZZA SPRINKLE
(valbenazine) capsules
40 mg
30 capsules
Rx Only
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b1ba7d64-e59c-4a2d-96ce-91048f9b6bee"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>NDC 70370-4060-1<br/>INGREZZA SPRINKLE<br/>(valbenazine) capsules<br/>60 mg<br/>30 capsules<br/>Rx Only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000016"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <observationMedia ID="MM03000016">
                     <text>NDC 70370-4060-1
INGREZZA SPRINKLE
(valbenazine) capsules
60 mg
30 capsules
Rx Only
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="1d2bc30b-cfc3-47f4-b094-1c1153f372de"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>NDC 70370-4080-1<br/>INGREZZA SPRINKLE<br/>(valbenazine) capsules<br/>80 mg<br/>30 capsules<br/>Rx Only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000017"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <observationMedia ID="MM03000017">
                     <text>NDC 70370-4080-1
INGREZZA SPRINKLE
(valbenazine) capsules
80 mg
30 capsules
Rx Only
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="valbenazine-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>